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ABSTRACT  
   
Cancer is a disease that affects millions of people worldwide each 
year. The metastatic progression of cancer is the number one reason for 
cancer related deaths. Cancer preventions rely on the early identification 
of tumor cells as well as a detailed understanding of cancer as a whole. 
Identifying proteins specific to tumor cells provide an opportunity to 
develop noninvasive clinical tests and further our understanding of tumor 
biology. Using liquid chromatography-mass spectrometry (LC-MS/MS) a 
short peptide was identified in pancreatic cancer patient plasma that was 
not found in normal samples, and mapped back to QSOX1 protein. 
Immunohistochemistry was performed probing for QSOX1 in tumor tissue 
and discovered that QSOX1 is highly over-expressed in pancreatic and 
breast tumors. QSOX1 is a FAD-dependent sulfhydryl oxidase that is 
extremely efficient at forming disulfide bonds in nascent proteins. While 
the enzymology of QSOX1 has been well studied, the tumor biology of 
QSOX1 has not been studied. To begin to determine the advantage that 
QSOX1 over-expression provides to tumors, short hairpin RNA (shRNA) 
were used to reduce the expression of QSOX1 in human tumor cell lines. 
Following the loss of QSOX1 growth rate, apoptosis, cell cycle and 
invasive potential were compared between tumor cells transduced with 
shQSOX1 and control tumor cells. Knock-down of QSOX1 protein 
suppressed tumor cell growth but had no effect on apoptosis and cell 
cycle regulation. However, shQSOX1 dramatically inhibited the abilities 
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both pancreatic and breast tumor cells to invade through Matrigel in a 
modified Boyden chamber assay. Mechanistically, shQSOX1-transduced 
tumor cells secreted MMP-2 and -9 that were less active than MMP-2 and 
-9 from control cells. Taken together, these results suggest that the 
mechanism of QSOX1-mediated tumor cell invasion is through the post-
translational activation of MMPs. This dissertation represents the first in-
depth study of the role that QSOX1 plays in tumor cell biology. 
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CHAPTER 1 
INTRODUCTION 
Cancer is heterogeneous disease that, at the most basic levels of 
detection and treatment, presents researchers and clinicians with a myriad 
of challenges. While tumor heterogeneity makes it difficult to identify one 
or two tumor specific biomarkers or therapeutic targets, it certainly 
provides researchers with exciting opportunities to understand complex 
genetic and post-translational mechanisms that drive growth and 
development. Understanding of how these genetic events lead to initiation 
and progression of cancer are key to the development of prognostic 
biomarkers and tumor specific inhibitors that can arrest tumor cell growth.  
 Advances in cancer research in the past 30 years have produced a 
complex and sometimes overwhelming body of knowledge, detailing 
characteristics that drive cancer progression. As research continues our 
understanding of complex networks that drive tumor progression need to 
be organized into characteristics that are common among tumors. This will 
lead to the logical progression of new findings in research to anti-
neoplastic therapeutics (bench to bedside), where the complexities of the 
disease can be understood in terms of the underlying principles termed 
“The Hallmarks of Cancer”. In a seminal review, Douglas Hanahan and 
Robert A. Weinberg provide a rational for the characterization of the traits 
that are common to most tumors such as: self sufficiency in growth 
signals, insensitivity to anti-growth signals, evasion of cellular apoptotic 
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mechanisms, limitless replicative potential, sustained angiogenesis and 
tissue invasion and mestastasis (Hanahan and Weinberg). As research 
continues the hallmarks of cancer will undoubtedly expand into areas of 
cellular energetics, genome instability, inflammation, evasion of immune 
destruction mechanisms and the role of the tumor microenvironment in 
tumor cell proliferation and metastasis (Hanahan and Weinberg). The 
recent increased efficiency of proteomic and genomic analysis has greatly 
expanded our discovery of novel proteins and genes expressed during 
cancer progression. The hallmarks of cancer provide us with a starting 
point at which to evaluate how over-expression of one gene or protein 
plays a role in tumor development. 
 
Autonomous Proliferative Signaling   
 Arguably, one of the most fundamental traits of a dysplastic cell is 
growth autonomy. Normal cells rely on autocrine or paracrine mitogenic 
signals to initiate growth. Transmembrane receptors such as receptor 
tyrosine kinases interact with growth factors initiating a cascade of events 
that drive cellular growth (Witsch, Sela, and Yarden). Epithelial cells rely 
on numerous integrins that interact with basement membrane components 
and extracellular matrix proteins to initiate, as well as terminate, 
proliferation (Lemmon and Schlessinger).  
In contrast, tumor cells show a reduced dependence on external 
mitogenic factors to proliferate, often generating their own stimulatory 
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signals decreasing their dependence on growth factors. Proliferative 
autonomy disrupts key homeostatic mechanisms that ensure controlled 
cell growth, death and tissue development and maintenance. There are 
three common strategies that tumor cells utilize to achieve growth 
autonomy: alterations in external growth signals, hypersensitive cell 
membrane transducers of those signals, and constitutive expression of 
intracellular signals that translate growth signals into uncontrolled cellular 
proliferation (Witsch, Sela, and Yarden).  
 The majority of normal cells receive growth signals in a paracrine 
manner from neighboring cells.  Tumor cells are able to create autocrine 
signals to support their growth. This eliminates their dependence on 
neighboring cells to proliferate. Although tumor-stroma interaction have 
recently been shown to play a role in growth and drug resistance (Place, 
Huh, and Polyak; Zhang and Huang). New cell culture techniques are only 
recently allowing us to fully appreciate the role of accessory cells and 
extracellular components on tumor cell growth. Undoubtedly as this area 
of research expands it will further shape how we view growth automomy. 
Platelet derived growth factor (PDGF) is an example of a protein that is 
normally generated and secreted by stromal cells (Compagni and 
Christofori).  In gliobastomas and sarcomas PDGF is produced 
independently by the tumor cell and has been shown to drive tumor cell 
proliferation (Compagni and Christofori).  
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Research over the past 10 years has seen minimal advances in 
understanding the identities and sources of these proliferative signals. 
This is in part due to the current methods used to analyze tumor cell 
behavior. The majority of research on tumor cells is performed in 2-D 
monocultures, which does not take into account cell number, position, 
neighboring cells of different origin and the compounding proteases and 
other enzymes that sequester and release growth factors from the 
pericellular space.  However, autocrine mechanisms of sustained 
proliferative tumor cell signaling is better understood than paracrine 
(Lemmon and Schlessinger; Witsch, Sela, and Yarden). Tumor cells have 
developed the ability to generate their own growth factor ligands. In 
conjunction with the overexpression of growth factor ligands, tumor cells 
may also overexpress cell surface receptors for those ligands.  This 
renders the tumor cell hyperreseponsive to otherwise limiting amounts of 
growth factors (Witsch, Sela, and Yarden; Cheng et al.).  
Transmembrane receptors such as epidermal growth factor-
receptor (EGF-R) transduce growth stimulatory signals through receptor 
tyrosine kinase activity (Lemmon and Schlessinger; Wheeler, Dunn, and 
Harari). In breast tumors, members of the EGF family (EGF-R/erbB and 
Her2/neu) are responsible for uncontrolled proliferation and ligand-
independent growth through the mitogen activated protein (MAP)-kinase 
pathway. Overexpression of EGF-R propagates growth autonomy through 
signal transduction in the cytoplasm that influences cellular behavior: 
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proliferation, metastasis, evasion of apoptotic mechanisms and cell cycle 
regulation (Witsch, Sela, and Yarden; Wheeler, Dunn, and Harari). 
 Increased efficiency of high-throughput and next generation DNA 
sequencing has led to the identification of somatic mutations in receptor 
tyrosine kinases and their downstream mitogenic pathways. In melanoma 
approximately 40% of tumors express mutations in B-Raf resulting in the 
constitutive signaling of the downstream MAP kinase pathway (Davies and 
Samuels). Targeting of these growth receptors specifically B-Raf and their 
downstream pathways has led to tremendous responses in treatment of 
patients with melanoma. Short interfering RNA (siRNA) and small 
molecule targeting of B-Raf in patients with advanced melanoma results in 
immediate regression, within 14 days, of the initial treatment (Flaherty et 
al.). This not only underscores the advantages that receptor tyrosine 
kinase pathways provide to tumor but also demonstrates how the 
inhibition of constitutive growth signals can restore negative feedback 
mechanisms that normally ensure proper growth regulation.  
 
Circumvention of Anti-Growth Signaling 
  Phenotypically connected to growth autonomy is the ability of 
tumor cells to circumvent anti-proliferative signaling. Anti-proliferative 
signaling is designed to maintain cellular quiescence and tissue 
homeostasis. Functionally anti-proliferative signals act in two ways to 
maintain tissue homeostasis; through soluble growth factor inhibitors or 
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through cell surface receptors either on the cell surface or that of 
neighboring cells thus forcing cells into a quiescent state (G0) 
(WEINBERG). For tumor cells to thrive they must overcome these anti-
proliferative signals. The majority of these proteins are associated with cell 
cycle, specifically the transition from G1 to S phase (Williams and 
Stoeber).  
 Cancer researchers over the past 30 years have validated dozens 
of tumor suppressors through gain- or loss-of-function studies. Two of the 
most well characterized tumor suppressor proteins are Retinoblastoma-
associated protein (RB) and TP53 (Lipinski and Jacks; Ghebranious and 
Donehower). Both RB and TP53 are key molecules that regulate cell fate 
decisions (Lipinski and Jacks; Ghebranious and Donehower).  
The RB protein integrates multiple signals from external and 
internal cues that dictate the ability of a cell to proliferate. The absence to 
RB function by mutation or deletion leads to unchecked cell cycle 
progression by multiple mechanisms (WEINBERG). In contrast to RB, 
TP53 mainly functions through internal cues such as stress and cellular 
abnormality sensors relating to excessive genome damage or suboptimal 
oxygenation (Ghebranious and Donehower). TP53 can then act to halt cell 
cycle progression until normal conditions are restored. If there is a failure 
to restore the cell to normal levels TP53 ultimately will trigger apoptosis. 
Although the majority of tumors posses mutations in either RB and/or 
TP53 it is unquestionable that these two proteins function only in the 
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context of a larger network. RB and TP53 null mice have been shown to 
develop normally and are surprisingly free of proliferative abnormalities 
until late in their lives (Lipinski and Jacks; Ghebranious and Donehower). 
These results reflect redundant signaling mechanisms within the cell. 
Emphasizing that tumor cells are the result of multiple mutations within 
redundant pathways ultimately leading to cancer.  
 
Elusion of Cell Death 
Overwhelming evidence supported by in vivo and in vitro models 
demonstrates that in addition to acquired proliferative abilities all tumor 
cells develop the ability to evade cellular apoptotic, autophagic and 
necrotic pathways (Saikumar et al.; Zörnig et al.). The most well 
characterized method of cell death is apoptosis. Apoptosis is a genetically 
predetermined mechanism for programmed cell death. Cellular conditions 
regulating apoptosis are monitored through external (extrinsic) and 
internal (intrinsic) pathways (Saikumar et al.). The extrinsic pathway is 
triggered by ligand-induced activation of death receptors at the cell 
surface (Saikumar et al.). The intrinsic pathway is the result of intracellular 
cascade of events leading to mitochondrial membrane permeabilization 
(Saikumar et al.).  Each apoptotic pathway can be divided into three 
phases based on caspase activation: initiation, integration/decision, and 
execution/degredation (Saikumar et al.). Both pathways ultimately lead to 
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cell shrinkage, chromatin condensation, mitochondrial membrane 
disruption, and nuclear fragmentation.  
Extrinsic apoptosis involves ligand activation of death receptors 
and/or dependency receptors on the cell surface (Saikumar et al.; Zörnig 
et al.). Activation of death receptors, tumor necrosis factor (TNF) family 
members, causes the Fas-associated death domain-containing protein 
(FADD) to associate with and oligomerize with the death inducing 
signaling complex (DISC). DISC then binds the initiator caspases 8 and 
10, leading to dimerization and activation of effector/executioner caspases 
3, 6, and 7. Rapid caspase activation coming from dependency receptors 
(e.g. netrin-1), leads to direct activation of effector/executioner caspases 
(Plati, Bucur, and Khosravi-Far).  
The majority of cell death in vertebrates proceeds through the 
intrinsic apoptotic pathway (Zörnig et al.). The intrinsic pathway is initiated 
due to DNA damage (nuclear activation). Caspase-2 migrates to the 
mitochondria causing membrane permeabilization allowing proteins from 
the inner membrane space (IMS) to be released into the cytosol (Garrido 
et al.). The intrinsic pathway is also activated by ER stress that releases 
calcium (Ca2+) into the mitochondria causing cytochrome c release and 
outer membrane (OM) permeabilization (Garrido et al.). Once the IMS 
proteins enter the cytosol they follow three distinct paths to induce 
apoptosis 1.) cytochrome c promotes the activation of the “apoptosome” 
complex by recruiting the initiator caspase-9 and apoptosis protease 
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activating factor-1 (APAF-1) as well as ATP/dATP. Activated caspase-9 
then catalyzes the activation of effector caspases 3, 6, and 7.  2.) 
Caspase-independent apoptosis occurs through apoptosis-inducing factor 
(AIF) and endonuclease G (EndoG). These proteins translocate into the 
nucleus initiating DNA fragmentation and chromatin condensation. 3.) 
Lastly, second mitochondria-derived activator of caspase/direct IAP 
binding protein with low pI (Smac/DIABLO) and Omi stress-regulated 
endoprotease/high temperature requirement protein A2 (Omi/HtrA2), 
initiate apoptosis indirectly by binding and sequestering inhibitor of 
apoptosis protein (IAP) allowing effector caspase activation (Garrido et 
al.). 
Cross talk between the extrinisic and intrinsic pathways has been 
extensively studied. The main link between the extrinsic and intrinsic 
pathways is initiated through the proteolytic cleavage of Bid. Bid, a 
member of the BCL-2 homology domain (BH3) family and is known to 
interact with members of the Bcl-2 family (Bax, Bak, Bcl2 and Bcl-XL) 
through the BH3 domain. Full length Bid (26 kDa) is cleaved by caspase-8 
into 11 and 15 kDa products. The 15 kDa (tBid) fragment contains the 
functional BH3 domain that can still interact with member of the Bcl-2 
family. There are two ways in which tBid can activate mitochondrial 
apoptosis: 1) tBid can directly interact with the OM, causing pore formation 
and the subsequent release of cytochrome c. 2) tBid can interact with the 
anti-apoptosis Bcl-XL through its BH3 domain preventing the formation of 
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the anti-apoptosis complex. This allows Bax activation and pore formation 
in the OM. (Saikumar et al.; Zörnig et al.; Plati, Bucur, and Khosravi-Far)  
 Tumor cells have developed multiple ways to prevent the release of 
cytochrome C. Tumor cells have been shown to overexpress Bcl-2 (BH3-
only) family members or disrupt the FAS ligand signaling circuit (Plati, 
Bucur, and Khosravi-Far). One of the most commonly occurring traits is 
the loss or mutation of tumor suppressor proteins such as TP53. TP53 
induces apoptosis due to DNA damage through the upregulation of BH3-
only proteins, Noxa and Puma (Saikumar et al.). The loss of TP53 function 
eliminates this DNA damage sensor from the apoptotic circuitry. Tumors 
may also overexpress anti-apoptotic regulators (Bcl-2, Bcl-XL) or survival 
proteins Insulin growth factor 1/2 (Igf-1/2) through the downregulation of 
proapoptotic factors (Bax, Bim and Puma) (Zörnig et al.). To circumvent 
the extrinsic apoptotic pathway tumor cells have been shown to either 
short circuit the Fas receptor or present a decoy receptor (Plati, Bucur, 
and Khosravi-Far). The redundancy at which tumor cells evade cellular 
apoptosis directly reflects the diversity of apoptosis signaling mechanisms 
that tumor cells encounter as they evolve to a malignant state.  
 Autophagy represents an alternative to apoptosis in which cells 
under stress (e.g. nutrient deficiency) will break down cellular organelles. 
This allows the cellular catabolites to be recycled and used for 
biosynthesis and energy metabolism (Kundu and C. B. Thompson). 
Intracellular vesicles termed autophagosomes envelop organelles 
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subsequently fusing with lysosomes where degradation occurs. The low 
molecular weight metabolites that are generated are used to support the 
cell in nutrient deprived environments similar to the environment created 
by tumor formation. 
 Numerous pathways have been uncovered detailing the crosstalk 
between autophagy and apoptosis. Similar proteins that inhibit apoptosis 
(PI3 kinase, AKT and mTOR kinase) also work to prevent autophagy 
(Kundu and C. B. Thompson). One essential protein important for 
autophagosome formation is Beclin-1. Beclin-1 is a member of the BH3-
only subfamily of apoptotic regulatory proteins. The BH3 domain allows it 
to bind to Bcl-2 proteins. Under cellular stress Beclin-1 is displaced from 
Bcl-2 triggering autophagy (Kundu and C. B. Thompson).  
 Research into autophagy has revealed that tumor cells utilize the 
autophagy pathway to survive in a nutrient depleted environment. 
Paradoxically, autophagy levels are induced in patients being treated with 
radiotherapy and chemotherapy, impairing rather than enhancing the 
killing of tumor cells (Hanahan and Weinberg; Kundu and C. B. 
Thompson). While the role of autophagy in tumor cells is just now 
emerging, future research will clarify the genetic and physiological 
conditions that lead to autophagosome formation and how autophagy 
enables cancer cells to survive or how it leads to cell death.  
 Necrosis in contrast to apoptosis and autophagy causes a cell to 
expand and explode, releasing their cellular contents into the tumor 
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microenvironment (MD). Previously, the role of necrosis in tumor cells was 
viewed solely in the terms of cell death. Recent research indicates that 
necrosis is under genetic control under certain circumstances rather than 
a random event (Hanahan and Weinberg). A consequence of necrosis is 
the release of inflammatory and pro-growth (IL-1α) signals to neighboring 
cells (MD; Zörnig et al.). These signals have been shown to recruit tumor 
promoting immune inflammatory cells, as well as contributing to 
angiogenesis, proliferation and invasiveness (MD; Kundu and C. B. 
Thompson). The precise role of necrosis in promoting tumor proliferation 
is still under study, but chronic inflammation has been shown to drive 
tumor growth. It is clear that while necrosis appears to be a counter-
balance to tumor formation, it may actually promote tumor expansion.     
 
 Boundless Replicative Immortality  
 The ability of tumor cells to develop growth autonomy and to evade 
cellular apoptotic mechanisms, detaching itself from normal regulatory 
mechanisms is not enough to acquire limitless replicative potential. Early 
work by Hayflick and colleagues in cell culture models demonstrated that 
normal cells have a finite passage number (Hayflick). Once cell 
populations reach their finite doubling time they enter into senescence or a 
quiescent state.  
 Work in vivo and in vitro has demonstrated two main mechanisms 
for tumor cells to overcome a senescent state. Tumor cells have been 
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shown to either disable RB and TP53 tumor suppressors or increase the 
expression of telomerase allowing these cells to evade cellular 
senescence and continue to replicate (Artandi and DePinho). As the cells 
begin to reach their finite passage number (average 60-70 for normal 
human cells) they enter a crisis state characterized by massive cell death 
(Artandi and DePinho). Wright and colleagues demonstrated that 
approximately 1 in 107 cells emerge from this crisis state with the ability to 
replicate without limit (Hayflick). Numerically, 60-70 doublings by tumor 
cells should be enough to exceed the number of cells in the human body. 
Two conclusions can be made from ongoing research into senescence; 
first that cellular senescence is emerging as a protective barrier to 
neoplastic expansion and second that the number of cells in a tumor does 
not represent the total amount of tumor cells needed to produce a 
malignancy.  
 
Angiogenesis 
 Oxygen and nutrients provided by the vasculature are essential to 
normal growth and development. The process of angiogenesis addresses 
this need for normal cells and tumor cells to excrete their waste and take 
up fresh oxygen and nutrients. During development of the vasculature 
endothelial cells assemble into tubes (vasculogenesis) leading to the 
branching of new vessels (angiogenesis) from the existing vascular 
structure (Lin et al.). After embryological and mature development, 
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expansion of the vasculature remains largely quiescent (Baeriswyl and 
Christofori). The exceptions are angiogenesis after injury, during wound 
healing and female reproduction (Baeriswyl and Christofori). In contrast, 
tumor expansion is dependent on the development of angiogenesis that 
brings a blood supply to the tumor (Weis and Cheresh). 
 As tumors increase in mass an “angiogenic switch” takes place 
leading to the constitutive expression of pro-angiogenic factors and the 
downregulation of anti-angiogenic factors (Hanahan and Folkman). The 
angiogenic switch is regulated by soluble factors and their cell surface 
receptors (integrins). In addition to cell surface adhesion molecules that 
interact with neighboring cells and basement membrane proteins, 
proteases cleave extracellular matrix proteins and cell surface receptors 
producing pro-angiogenic peptides (Baeriswyl and Christofori).  
 Vascular endothelial growth factor (VEGF) is the most common 
angiogenic stimulatory molecule produced during tumorigenesis. The 
VEGF gene encodes three tyrosine kinase receptors (VEGFR-1-3) 
(Hanahan and Weinberg; Weis and Cheresh).  VEGFR are involved in the 
generation of new blood vessels from embryonic development through the 
physiological and pathological circumstances in adults (Lieu et al.). VEGF 
signaling is regulated and induced on multiple levels either during hypoxic 
or nutrient deprived situations as well as by oncogenic signals (Cross and 
Claesson-Welsh; Lieu et al.). VEGF in its latent form can also be released 
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and activated by matrix metalloproteases (MMP) leading to sustained 
tumor angiogenesis (Lieu et al.).  
 In contrast there are numerous anti-angiogenic factors that work to 
tightly regulate aberrant angiogenic signaling. Thrombospondin-1 (TSP-1) 
as well as angiostatin are two well-known examples of proteins that 
counterbalance the angiogenic switch (Taraboletti et al.; Bauvois). They 
both work by binding to transmembrane receptors on endothelial cells 
inducing a suppressive signal to counteract the pro-angiogenic signals 
(Taraboletti et al.). Research over the past 30 years has led to the 
identification of numerous endogenously produced angiogenic inhibitors 
(Weis and Cheresh; Baeriswyl and Christofori; Keleg et al.). Transgenic 
mouse studies have shown that the loss of genes that encode these 
inhibitors by themselves does not result in autonomous growth but rather 
enhances the growth of implanted tumors (Weis and Cheresh). If the 
concentration of the circulating angiogenic inhibitors is increased, tumor 
growth is impaired as well as wound healing abilities (Weis and Cheresh). 
Current research suggests that endogenous angiogenesis inhibitors under 
normal circumstance help to control transient angiogenic capabilities 
during wound healing and that they also act to control angiogenesis in 
persistent tumors.  
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Tumor Cell Invasion and Metastasis 
 The ability of primary tumor cells to degrade the basement 
membrane components, invade into adjacent tissue or circulate in blood 
leading to a secondary metastatic site of tumor growth are the cause of 
90% of human cancer deaths (Hanahan and Weinberg). Invasion and 
metastasis provide tumors with the ability to escape their nutrient depleted 
environment and colonize nutrient rich areas of the body. As tumor cells 
progress to a higher pathological grade there is a clear shift in cellular 
morphology that is reflected at the transcriptional and translational level. 
While the specific processes of invasion and metastasis are still poorly 
understood, recent advances in experimental models have broadened our 
overall context of the metastatic cascade.  
 The process of invasion and metastasis is performed as discrete 
steps involving cellular and metabolic changes. As a tumor cell progresses 
toward a metastatic phenotype, it undergoes a morphological change from 
a cuboidal shape (epithelial) to a more elongated (mesenchymal) shape 
(Bacac and Stamenkovic). There is a succession of events starting with 
the local invasion of tumor cells into neighboring blood vessels 
(intravasation) followed by the migration of the tumor cells through the 
lymphatic and hematogenous system (Talmadge and Fidler). The tumor 
then escapes the vessels into distant tissues (extravasation) where it 
recolonizes (colonization) as micrometastatic lesions eventually growing 
into macroscopic tumors (Talmadge; Bacac and Stamenkovic).   
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 The developmental process of epithelial-to-mesenchymal transition 
(EMT) has now become widely accepted as one of the primary means in 
which tumor cells acquire the ability to invade and disseminate into local 
and distant tissue (Bacac and Stamenkovic; Kokkinos et al.). Tumor cells 
can shift to a mesenchymal state either stably or transiently during the 
process of metastasis (Sarrio et al.), where upon extravasation plasticity in 
the EMT process allows the reversal back to an epithelial state resulting in 
the formation of a new tumor colony. EMT in tumor cells is characterized 
by a “cadherin-switch” where E-cadherin is replaced by N-cadherin driving 
growth and invasion (Blick, Widodo, Hugo, Waltham, Lenburg, Neve, and 
E. W. Thompson; Royer and Lu; Katz et al.). E-cadherin, a cell-to-cell 
adhesion molecule is one of the best-characterized alterations in invading 
tumor cells (Solanas et al.). In normal cells E-cadherin regulates growth 
and invasion through its transmembrane receptor, forming adherent 
junctions with neighboring cells and basement membrane proteins 
(Zeisberg and Neilson). The binding of E-cadherin with neighboring cells 
leads to an increase in anti-growth signals via its cytoplasmic interaction 
with β-catenin (Solanas et al.). Loss of E-cadherin in the majority of tumor 
cells either by proteolytic cleavage (metalloproteases and cysteine 
cathepsin proteases) of the extracellular domain or through transcriptional 
repression (Snail, Slug, Twist and Zeb1/2) result in the release of β-
catenin into the nucleus up-regulating pro-growth signals (Royer and Lu; 
Moreno-Bueno et al.; E. S. Radisky and D. C. Radisky).  
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 A decrease in E-cadherin is accompanied by an increase in N-
cadherin, a protein that is normally associated with migrating neurons and 
mesenchymal cells during development (Kalluri and Weinberg). A 
structural shift is also a hallmark of EMT documented by the transition of 
interfilament proteins, such as keratin to the more invasive filament, 
vimentin (Kalluri and Weinberg). While it is widely accepted that EMT 
plays a large role in tumor cell metastasis the extent to which individual 
components such as transcription factors, cadherins and structural 
proteins initiate and drive tumor cell metastasis is still under investigation.  
 Although the expression of EMT promoting transcription factors as 
well as the structural changes associated with EMT have been observed 
in the majority to epithelial tumors, it is not the only mechanism at which 
tumor cells develop invasive potential. The contributions of the tumor 
microenvironment provide tumor cells with proteases and pro-invasive 
factors that alleviate the need for tumor cells to independently generate 
invasive proteins. MMPs represent the most studied proteases that 
contribute to enhanced growth and metastasis in tumor cells.  
 MMPs are a family of 28 conserved zinc-associated proteinases 
that are classified into six groups based on sequence homology as well 
the substrates in which they primarily degrade  (Tallant, Marrero, and 
Gomis-Rüth). Most MMPs are thought to be secreted in an inactive form 
from either stromal cells or epithelial cells and then activated in the 
extracellular environment (Kessenbrock, Plaks, and Werb). Activation of 
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MMPs occurs through a process called “cysteine switch” in which Cys73-S-
Zn in the latent MMP is a site of cleavage, exposing a zinc ion.  Further 
folding of the MMP after cleavage of the pro-domain activate the catalytic 
domain (Kessenbrock, Plaks, and Werb).  
 The activity of MMPs is regulated by several types of inhibitors, but 
the majority of the work is done by tissue inhibitors of MMP (TIMP) 
(Snoek-van Beurden and den Hoff; Kessenbrock, Plaks, and Werb). The 
TIMPs are also secreted proteins but can be found bound to the surface of 
cells in tight association with MT-MMP (Snoek-van Beurden and den Hoff; 
Kessenbrock, Plaks, and Werb). The balance between the MMPs and 
TIMPs is what is largely responsible for regulating degredation of the 
extracellular matrix proteins (Kessenbrock, Plaks, and Werb). 
Deregulation of the MMPs is a characteristic of numerous pathological 
conditions including tumor cell invasion (Köhrmann et al.; Zeisberg and 
Neilson).  
 The extent and mechanism to which these processes of invasion 
contribute to metastasis are currently poorly understood. As metastatic 
models continue to evolve it is undeniable that all of these process 
described above will interconnect primary tumor invasion and metastasis 
in multiple ways.   
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Therapeutic Strategies 
 An understanding of how the hallmarks of cancer are intertwined 
and contribute to cancer progression has led to tremendous advances in 
targeted cancer therapeutics. While my thesis does not yet describe the 
use of quiescin sulfhydryl oxidase 1 (QSOX1) as a viable target for cancer 
therapy I feel that it is important to briefly discuss how a molecular 
understanding of the required traits for cancer development have led, in 
one example, to success and failure in cancer treatment. The recent 
development of monoclonal antibody and small molecule inhibitors 
directed towards a specific receptor (receptor tyrosine kinases) or protein 
resulting in successful regression of primary tumors has validated the 
importance of particular hallmark capabilities (Lemmon and Schlessinger). 
At the same time we have also seen that specific molecular targeting while 
leading to fewer off-target effects often times has a transitory response 
eventually followed by a relapse (Lemmon and Schlessinger; Hanahan 
and Weinberg). The previously described clinical trial involving siRNA 
targeting of B-Raf in melanoma patients exemplifies this point (Flaherty et 
al.). Initial treatment of advanced melanoma patients using B-Raf 
inhibitors leads to an immediate remission in 90% of patients within 14 
days of treatment. While treatment of melanoma with B-Raf inhibitors is 
initially successful almost all patients experience a relapse within two 
years of their initial treatment (Flaherty et al.). Follow up research into 
patients that relapsed found that the tumor cells had adapted to the 
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treatment, utilizing an alternative pathway to drive proliferation through 
MAPK, a key growth factor in a tumor cells ability to develop growth 
autonomy (Flaherty et al.). The results of this clinical trial while extremely 
impressive emphasize the ability of a tumor cell to adapt to specific 
treatments utilizing redundant pathways. As we continue to mine for 
cancer specific biomarkers using advances in genomic and proteomic 
technologies our understanding of tumor promoting pathways will most 
likely lead to the progression of the combinational targeting of multiple 
biochemical pathways. A comprehensive understanding of the web of 
pathways will allow researchers to target the same pathway in multiple 
ways completely alleviating the tumor burden. 
 
Plasma Biomarker Discovery 
 The ability to develop clinical tests that can detect cancer at its 
early stages is equally dependent on the discovery of novel biomarkers as 
it is on understanding the phenotypes that enable and drive tumor 
progression. As previously discussed hallmark traits such as growth 
autonomy, angiogenesis and metastasis are often driven by short peptides 
cleaved from the cell surface and basement membrane components as 
well as whole proteins secreted by the local tumor microenvironment and 
the primary tumor. Because blood circulates through every organ of the 
body, sampling normal and tumor proteins, it provides a logical source to 
mine for tumor specific biomarkers.  
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 Cancer is generally a disease of probability in which the earlier one 
is able to detect disease the higher the success rate in curing the disease 
with surgery and/or other therapies.  Early stage tumors may not have 
metastasized, for example. Mining for biomarkers in patient plasma is very 
difficult due to the complexity of highly abundant proteins which obscure 
less abundant potential biomarkers that could give unique insight into 
normal versus disease. By filtering out the more abundant plasma proteins 
in cancer patient samples we were able to find several peptide fragments 
that were not present in control plasma. We then used liquid 
chromatography-tandem mass spectrometry (LC-MS/MS) to identify the 
peptides. Our initial screen identified a unique peptide 
(NEQEQPLGQWHLS) that was consistently found in patient samples but 
not in normal control samples. By performing a BLAST search we were 
able to map this short peptide back to the parent protein QSOX1-L. The 
NEQEQPLGQWHLS peptide was found in 16 of 23 ductal 
adenocarcinoma patients (DAP), 4 of 5 patients with intraductal papillary 
mucinous neoplasm (IPMN), thought to be a precursor to pancreatic 
ductal adenocarcinoma (PDA) but this peptide was not found in any of the 
42 normal healthy donor samples using the same method (Figure 1).  
 We then performed immunohistochemistry (IHC) on paraffin 
embedded sections from patients who underwent surgical resection for 
PDA (Figure 1). We were able to show using a polyclonal antibody to 
QSOX1 that staining with QSOX1 is very specific to dysplastic cells within 
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the pancreatic duct and not expressed in adjacent normal cells (Figure 1). 
QSOX1 protein is not only expressed in the pancreas but it is also weakly 
expressed in normal transformed cell lines as well as being highly 
expressed in cancer cell lines such as breast, prostate, colon, brain, and 
lung. We have also found through western blot analysis of total cell lysate 
that peripheral blood mononuclear cells (PBMC) taken from a healthy 
individual do not express QSOX1 but when you treat PBMC’s with the 
mitogen, phytohemagglutin (PHA), QSOX1 becomes weakly expressed. 
Initially concluding that QSOX1 is activated through cellular stress, 
possibly as a mechanism to control cellular proliferation. QSOX1 is a 
protein that has been shown to be expressed at a very low level if at all in 
normal tissue but is expressed either due to reactive oxygen species in 
the cell or mitogen stimulation and is highly expressed in a variety of 
cancers with extremely specific staining in the dysplastic cancer cells 
(Antwi, Hostetter, Demeure, Katchman, Decker, Ruiz, Sielaff, Koep, and 
Lake).  
 QSOX1 protein was initially shown by our lab to be overexpressed 
in rapidly proliferating cells (tumor or mitogen stimulated cells), promoting 
cellular survival through an unknown mechanism (Antwi, Hostetter, 
Demeure, Katchman, Decker, Ruiz, Sielaff, Koep, and Lake; Morel et al.). 
Tumors arise from the inability of a cell to control proliferation as well as 
initiate apoptosis. Therapeutic intervention is often thwarted by the 
overexpression of proteins in response to anti-neoplastic agents that 
  24 
suppress apoptosis and activate cellular growth cascades that allow the 
primary tumors to thrive. By determining the role of QSOX1 in response to 
cellular homeostasis and cancer progression we hope to be able to use 
QSOX1 as a marker to indicate disease progression or potentially as a 
tool for therapeutic intervention in combination with current therapeutic 
regimens. Thus beginning our investigation on the function of the 
sulfhydryl oxidase QSOX1 as it relates to the above described hallmark of 
cancer traits.  
 
Sulfhydryl Oxidase Family 
 Sulfhydryl oxidases oxidize thiols in proteins during folding, 
reducing oxygen as the terminal electron acceptor (Fass). The human 
members of the sulfhydryl oxidase family that have been discovered to 
date exist as two functional isoforms produced through alternative splicing 
of ~100 amino acids before the 3’-UTR (Giorda et al.). The shorter protein 
generally resides in the cytoplasm while the longer protein contains a 
transmembrane domain and resides in the ER and/or mitochondria. Due 
to the difficulty in expressing and isolating the long form of each group 
member assumptions have been made but not validated for the individual 
functions of the two isoforms. Further studies need to be performed to 
understand the protein-substrate interactions that exist between these two 
isoforms, using peptide specific antibodies and/or thiol trapping 
experiments. 
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Disulfide bonds are required for the stability and function of many 
proteins. Comparative mutagenesis studies by the Fass and colleagues 
using Ero1p and Erv2p as  sulfhydryl oxidase representatives have 
revealed common mechanistic themes. Each member of the family 
contains a CXXnC motif (where X represents any amino acid and n 
represents varying distances between C) that directly interacts with the 
flavin adenine dinucleotide (FAD) cofactor, called the “active di-cysteine” 
to transfer electrons from the oxidation of sulfhydryl groups during protein 
refolding (Vitu et al.). Two additional CXXC motifs assist in directing 
protein-substrate interactions.  One CXXC that is directly downstream of 
the “active di-cysteine” assists in the protein-substrate interaction (Vitu et 
al.). A second termed the “shuttle di-cysteine” is situated outside of the 
four-helix-bundle core on a flexible hinge that assists in directing proteins 
from the solvent to the active site (Vitu et al.). Until recently, the majority of 
sulfhydryl oxidase research has focused on the biochemical properties of 
these proteins to efficiently form disulfide bonds. Although interest in the 
role of sulfhydryl oxidases in diseases progression has recently intensified 
in part due to their expression in cancers and heart disease (Katchman, 
Antwi, Hostetter, Demeure, Watanabe, Decker, Miller, Hoff, and Lake; 
Morel et al.; Mebazaa et al.).  
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Quiescin Sulfhydryl Oxidase 1  
QSOX1 belongs to the family of FAD-dependent sulfhydryl 
oxidases that are expressed in all eukaryotes sequenced to date (Thorpe 
et al.).  The primary enzymatic function of QSOX1 is oxidation of sulfhydryl 
groups during protein folding to generate disulfide bonds in proteins, 
ultimately reducing oxygen to hydrogen peroxide (Coppock, Cina-Poppe, 
and Gilleran; Coppock et al.; Heckler et al.). QSOX1 has been reported to 
be localized to the Golgi apparatus and endoplasmic reticulum (ER) in 
human embryonic fibroblasts where it works with protein disulfide 
isomerase (PDI) to help fold nascent proteins in the cell (Coppock and 
Thorpe).  
In the human genome, QSOX1 is located on chromosome 1q24 
and alternative splicing in exon 12 generates a long (QSOX1-L) and short 
(QSOX1-S) transcript (Figure 1) (Thorpe et al.). Both, QSOX1-S and -L 
have identical functional domain organization from the amino terminus as 
follows: two thioredoxin-like domains (Trx1 &2), a helix rich region (HRR) 
and an Erv/ALR FAD-binding domain (Coppock, Cina-Poppe, and 
Gilleran; Vitu et al.; Alon, Heckler, et al.). QSOX1-L contains a predicted 
transmembrane domain that is not present in QSOX1-S due to alternative 
splicing (Figure 1) (Alon, Heckler, et al.). QSOX1 was originally discovered 
in quiescent human lung fibroblasts and was hypothesized to aid in the 
transition from G0 to S phase of the cell cycle, a balance often altered in 
cancer cells (Hoober et al.). Since the initial discovery of QSOX1 the 
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majority of research to date has focused on detailing the sulfhydryl 
oxidase activity for disulfide bond formation in proteins. Thorpe and 
colleagues revealed the ability of QSOX1 to efficiently generate disulfide 
bonds into proteins during folding at rate of 1000 per minute with a KM of 
150uM per thiol (Heckler et al.; Alon, Grossman, et al.; Alon, Heckler, et 
al.). QSOX1 appears to play a significant role in redox regulation within 
the cell, although the in vivo biological substrates are undefined as well as 
the functional significance associated with each splice variant.  
 Redox state and redox regulation are important in embryo and fetal 
development as well as transcriptional and post-translational regulation in 
tumor progression (Andrade, Stolf, Debbas, Rosa, Kalil, Coelho, and 
Laurindo). In this context, QSOX1 may be involved in regulating the thiol-
disulfide exchange reactions during development helping to maintain an 
adequate redox state. Indeed, Portes and colleagues have found in mice 
during development, QSOX1 expression is restricted mainly to mesoderm 
and ectoderm derived tissues and that QSOX1 expression seems to be 
developmentally regulated, increasing with tissue maturation. Further 
studies involving QSOX1 and its role in development could also allow us 
to infer its functional significance in tumor cells. As it is very common for 
developmentally regulated proteins to provide growth and metastatic 
advantages to tumor cells. Numerous receptor tyrosine kinases, epithelial-
to-mesenchymal transition related transcription factors and basement 
membrane degrading proteases such as MMPs are activated in response 
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to H2O2 (Wu). The increase in QSOX1 expression in tumor cells could lead 
to the more oxidative environment commonly observed in tumor cells and 
surrounding stroma. 
In contrast, work by Morel and colleagues proposed that expression 
of QSOX1 protects MCF7 breast tumor cells from oxidative stress-induced 
apoptosis (Morel et al.). They show that expression of QSOX1 directly 
slows the growth of MCF7 cells and that it correlates with an increase in 
cell survival after treatment with H2O2 (Morel et al.). Initially these findings 
suggested that increased QSOX1 expression in tumor cells may allow 
them to actively evade cellular apoptotic mechanisms mediated by 
reactive oxygen species. As research into the role of QSOX1 in tumor 
cells progressed the importance of this paper, as a central hypothesis 
possibly explaining why we see an overexpression of QSOX1 in tumor 
cells, failed to satisfy follow up testing. Loss of QSOX1 in MCF7 cells did 
not result in an increase in reactive oxygen species as measured by 
DCFDA staining nor did we see that the loss of QSOX1 resulted in an 
increase in apoptosis.  
 In direct support of our discover of QSOX1 in pancreatic tumor cells 
Song and colleagues, through microarray analysis, discovered that 
QSOX1 is expressed early in prostate cancer progression (Song et al.). 
They found that the loss of NKX3.1 expression correlates with an increase 
in QSOX1 expression in prostate tumors. NKX3.1 is a homeobox 
transcription factor and a known tumor suppressor that is exclusively 
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expressed in luminal epithelial cells of the prostate. QSOX1 has been 
shown to be highly expressed in early stages of prostatic neoplasia and 
throughout prostate cancer progression, but was not present in normal 
prostate (Song et al.; Ouyang). NKX3.1 expression is decreased or absent 
in early stages of prostate tumor development and absent in up to 80% of 
metastatic prostate tumors (Ouyang). Since loss of NKX3.1 results in 
over-expression of QSOX1, it further emphasized the need to uunderstand 
the role QSOX1 activity may play in early tumorigenesis (Song et al.). 
 While the expression of QSOX1 in tumor cells has been observed 
in numerous microarray studies the majority of these groups have not 
attempted to determine the function of QSOX1 in normal or tumor cells. 
Thus in this thesis I strove to analyze the functional advantage that 
QSOX1 provides tumor cells through the analysis of the hallmarks of 
cancer traits detailed in the introduction. 
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Figure 1. Our experimental outline of the discovery and confirmation of 
QSOX1 as a pancreas specific tumor cell marker. QSOX1 was initially 
discovered in 3 kDa filtered pancreatic tumor patient plasma. The 
subsequent filtered plasma, containing peptides and proteins 3 kDa and 
smaller, was then analyzed using LC-MS/MS to identify peptides that are 
unique to patient plasma but not found in normal plasma. A short peptide 
NEQEQPLGQWHLS was repeatedly discovered (14 of 24 patients) in 
patient plasma and was not found to be present in normal plasma. This 
short peptide was mapped back to a larger parent protein QSOX1-L. To 
confirm out mass spectrometry data we performed IHC and western blot 
analysis using a polyclonal anti-QSOX1 antibody of pancreatic ductal 
adenocarcinoma surgically resected tissue and numerous tumor cell lines. 
Our IHC data revealed that QSOX1 is a pancreatic tumor cell specific 
marker and that QSOX1 is expressed at variable levels in numerous 
different tumor cell culture line (pancreas, breast, colon, lung and brain). 
The question remained, what advantage does QSOX1 provide to tumor 
cells? 
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CHAPTER 2 
METHODS TO ANALYZE THE ROLE OF QSOX1 EXPRESSION IN 
PANCREATIC AND BREAST ADENOCARCINOMA. 
Abstract 
 Our initial results indicated that QSOX1 is expressed in human 
pancreatic, breast, lung, and prostate adenocarcinomas but is not found in 
adjacent normal tissues. Subsequently we were able to show that QSOX1 
is also expressed at higher levels in pancreatic and breast 
adenocarcinoma cell lines compared to transformed normal cell lines 
(Figure 1). Fortunately expression of QSOX1 in in vitro cell lines mimicked 
that of our in vivo findings allowing us to use established cell lines to 
analyze the role of QSOX1 in tumor cells. Using RNA interference (RNAi) 
technology to degrade QSOX1 RNA and reduce QSOX1 protein 
expression we analyzed the role of QSOX1 as it relates to the hallmarks of 
cancer.  
 
Overview 
Loss-of-function studies using RNAi technology has revolutionized 
our ability to understand the role of specific genes and proteins (Carthew 
and Sontheimer). In the present study we utilized short hairpin RNA 
(shRNA) over conventional short interfering RNA (siRNA) to inhibit the 
expression of QSOX1. Utilization of shRNAs over siRNA provided us with 
three key features that gave us improved and reproducible results (a) 
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increased RNA degradation of QSOX1 (b) long term loss of QSOX1 (c) a 
DNA based system (shRNA) over an RNA based system (siRNA) 
alleviating concerns of RNase degradation providing highly reproducible 
results. 
RNAi machinery can be programmed exogenously or 
endogenously through the utilization of double stranded RNA (Carthew 
and Sontheimer; Silva et al.).  The most well characterized endogenous 
mechanism of gene inhibition is micro-RNA (miRNA) genes (Carthew and 
Sontheimer). In mammalian cells miRNAs are transcribed in the nucleus 
by RNA polymerase II leading to the generation of a long primary 
polyadenylated RNA (pri-miRNA) (Carthew and Sontheimer). The pri-
miRNA is then recognized and processed by the RNase III enzyme 
Drosha. Drosha cleaves the hairpin to produce a pre-miRNA 
approximately 70-90 nucleotides in length with a 2-nucleotide 3’ overhang 
(Carthew and Sontheimer). Proper processing of the pre-miRNA structure 
signals Exportin-5 to transport the pre-miRNA into the cytoplasm (Carthew 
and Sontheimer). In the cytoplasm the pre-miRNA structure is recognized 
and further processed by the enzyme Dicer to produce a mature miRNA of 
approximately 22 nucleotides. The mature miRNA is next recognized by 
the RNA induced silencing complex (RISC) that then targets and degrades 
your gene of interest leading to RNA and protein degradation (Carthew 
and Sontheimer; Silva et al.). Our current shRNA technology is designed 
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to function in the same manner as miRNA as well as utilizing key features 
found in strong miRNA such as miR-30 (Silva et al.).  
To analyze the role of QSOX1 in pancreatic and breast 
adenocarcinoma we generated multiple shRNAs targeting QSOX1 in a 
pLK0.1 lentiviral vector. The establishment of stable QSOX1 knock-down 
cell lines in pancreatic and breast adenocarcinoma provided us with a 
robust and long term knock-down model which we were able to take 
advantage of in our efforts to study the role of QSOX1 as it relates to the 
hallmarks of cancer. In the current chapter we describe the methods used 
to analyze how the loss of QSOX1 affect pancreatic and breast 
adenocarcinoma cell lines. 
   
Material and Methods 
Cell culture 
 Pancreatic adenocarcinoma BxPC3, PANC-1, CFPac-1, MiaPaca-2 
and Capan1 cancer cell lines were cultured in DMEM with 10% fetal 
bovine serum (FBS) (Gibco).  Immortal human non-tumorigenic pancreatic 
duct epithelial cells (HPDE6) were cultured in Clontech KGM-2 
karotinocyte media (Gibco). All cell lines were grown at 370C with 5% CO2.  
Breast adenocarcinoma MCF7, MDA-MB-468, MDA-MB-453, 
BT549 and MDA-MB-231 cancer cell lines were cultured in DMEM with 
10% fetal bovine serum (FBS) (Gibco).  Immortal human non-tumorigenic 
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breast epithelial cells (MCF10A) were cultured in Clontech KGM-2 
karotinocyte media (Gibco). All cell lines were grown at 370C with 5% CO2.  
All cell lines tested negative for mycoplasma contamination using, 
Venor GeM Mycoplasma Detection Kit, (Sigma).  
 
Immunohistochemistry (IHC) of Pancreatic Tissue 
Tissue from patients who underwent surgical resection for PDA 
were formalin-fixed and paraffin-embedded. The tissue blocks were 
sectioned at 5 µm thickness, transferred to slides and dried overnight at 
room temperature. The slides were dewaxed, rehydrated and antigen 
retrieved on-line on the Bond autostainer (Leica Microsystems, Inc., 
Bannockburn, IL). The 5 µm cut slides were baked at 60 °C for 60 min and 
subjected to heat induced epitope retrieval, in a peroxidase free 
environment, using a proprietary citrate based retrieval solution for 20 min. 
The slides were incubated for 30 min with rabbit polyclonal anti-QSOX1 at 
1:75 (Proteintech Group, Inc.,Chicago, IL). Each section was visualized 
using the Bond Polymer Refine Detection kit (Leica) using 
diaminobenzidine chromogen as substrate. Dr. Hostetter, a board-certified 
pathologist, evaluated each section using a standard scoring based on 
stain intensity (0-3) with 0 indicating no staining and 3 indicating strong 
staining. Stain localization in tumor cells were nuclear, cytoplasmic or 
membranous.  
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Immunohistochemistry (IHC) of Breast Tissue and Scoring of 
Staining Intensity  
Breast tumor microarray slides were generated from 153 different 
breast cancer patients.  Each patient’s tumor was represented in triplicate 
on the slides. Immunohistochemistry on breast tumor tissue microarray 
(TMA) samples was performed exactly as previously described for 
pancreatic tissue. After staining the TMA slides with anti-QSOX1 rabbit 
polyclonal antibody, a board certified pathologist (Dr, Idris Tolgay Ocal) 
scored the staining pattern as i) the percentage of cells with IHC staining 
for QSOX1 protein expression in the core tumor tissue sample (0: no 
staining, 1: 1-33%, 2: 34-66%, 3: 67-100%) and ii) the intensity of the 
antibody stain (0: no staining, 1: weak, 2: moderate, 3: strong staining 
intensity).  
 
Statistical Assessment of QSOX1 IHC with Molecular Subtypes of 
Breast Cancer  
There were 153 patient tissue samples in triplicate stained with 
anti-QSOX1 rabbit polyclonal Ab (Proteintech).  IHC staining was scored 
by a board certified pathologist (I.T.O.). The amount and intensity of 
QSOX1 staining/expression was scored on a scale of 0-3.  The first IHC 
score number represents the percentage of cells staining (0: No staining, 
1: 1-33%, 2: 34-66%, 3: 67-100%), and the second represents intensity (0: 
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No staining, 1: weak, 2: moderate, 3: strong staining intensity). We 
grouped the scores into 4 categories: 0, 11/12/21, 22/13/31 and 32/33/23. 
To evaluate the relationship between markers and QSOX, 
Pearson’s chi-square test was performed. Using 2-sided P values, 
statistical significance will be set at P ≤ 0.05. 
 
Generation of Short Hairpin (sh) RNA and Lentiviruses Production 
Three different shRNA for QSOX1 were obtained through DNASU 
(http://dnasu.asu.edu) already in the lentiviral pLKO.1-puromycin selection 
vector. QSOX1 sh742, 5’- 
CCGGGCCAATGTGGTGAGAAAGTTTCTCGAGAAACTTTCTCA 
CCACATTGGCTTTTTG - 3’ (sense), QSOX1 sh528, 5’- 
CCGGACAATGAAGAAGCCTTT - 3’ (sense), QSOX1 sh616, 5’- 
TCTAGCCACAACAGGGTCAAT -3’ (sense) and shScramble with target 
sequence 5’ –TCCGTGGTGGACAGCCACATG – 3’ was obtained from 
Josh LaBaer’s laboratory at Arizona State University. The target sequence 
is underlined and each vector contains the same supporting sequence 
surrounding the target sequence as indicated in sh742.  
 Lentiviruses containing sh742, sh528, sh616 and shScramble were 
produced using 293T cells. 293T cells were seeded at 1.5 x 106 cells per 
well in 2 mL media lacking antibiotics using a 6 well plate format and 
incubated at 37oC, 5% CO2 for 24 hrs. The following day the 293T cells 
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were transfected with 2500ng shRNA maxi-prepped plasmid DNA (Sigma 
GeneElute™ HP Plasmid Maxiprep Kit), 500ng VSVg, 2500ng d8.91(gag-
pol) in LT1 transfection reagent from Mirus Bio (Madison, WI) and 
centrifuged at 1000g for 30 minutes and incubated as 37oC, 5% CO2 for 
24 hrs at in media lacking antibiotics. The next morning media containing 
lentivirus was collected and replaced with complete media. Supernatants 
(2.5ml) from transfected 293T cells producing each sh lentivirus were 
collected every 24 hours for a total of 72 hours, combined and stored at -
20oC. 
 
Generation of shQSOX1-Transduced Tumor Cell Lines 
Stable transduction of sh742, sh528, sh616 and shScramble into 
BxPC-3, Panc-1, MCF-7 and BT549 cell lines was performed by first 
seeding the cells at 8 x 105 cells/well in a 6 well plate and incubating 
overnight. The next day the cells were transduced by adding 8ug/mL 
polybrene (Millipore) and 200ul sh742, sh528, sh616 and shScramble 
lentivirus media from 293T cells to each well. The cells were spun at 1000 
rpm for 30 minutes and then incubated for 24 hours. The following day 
fresh DMEM with 10% FBS was added, containing 1ug/mL puromycin 
(Sigma), to select for the transduced cells. QSOX1 knockdown was 
measured by western blot.  
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SDS-PAGE-Western blotting  
 Western blotting was performed using cell lysates from HPDE6, 
BxPC3, Panc-1, Capan1, CFPac1, MCF10A, MCF7, MDA-MB-468, MDA-
MB-453, BT549 and MDA-MB-231 cells as well as pancreatic cancer 
patients 1010 and 1016 tumor and adjacent normal enzymatic 
supernatant. Cell lysates were generated by harvesting 2.5 x 106 cells by 
centrifugation followed by lysis using RIPA buffer (50mM Tris-HCl, pH 7.4, 
150mM NaCl, 1mM EDTA, and 1% Triton X-100) with 1x SigmaFAST 
Protease Inhibitor Cocktail Tablet, EDTA Free. Protein in the cell lysate 
was measured using the micro BCA protein assay kit (Thermo Scientific). 
All samples were then normalized to 2ug/mL (20ug total protein per lane). 
Samples were run on 10% SDS-polyacrylamide gels then transferred onto 
Immun-Blot™ PVDF Membranes (Bio-Rad). Rabbit polyclonal anti-
QSOX1 (ProteinTech), rabbit polyclonal anti-Bactin and anti-alpha-tubulin 
(Cell Signaling), and rabbit polyclonal anti-MMP-2 and -9 (Sigma) antibody 
was diluted 1:1000, 1:1000, and 1:500 respectfully, in 0.1% BSA in 1x 
TBS+ 0.01% Tween-20 and incubated for overnight. Goat anti-rabbit IgG-
alkaline phospatase or HRP secondary antibody was used at a 1:5000 
dilution and incubated with the blot for 1 h followed by washing. BCIP/NBT 
substrate (Pierce Chemical, Rockford, IL) was added and the blot was 
developed at room temperature (RT) for approximately 1 hour, in samples 
incubated in alkaline phosphatase secondary antibody. For samples 
incubated in goat anti-rabbit HRP secondary the blots were developed 
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using Novex ECL Chemiluminescent Substrate Reagent Kit. Quantification 
of band intensity was measured using Image J and is presented as 
percent change from the scrambled shRNA control. All gel images were 
annotated and processed using Photoshop software. 
 
MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) 
Assay 
 Cells were seeded at 3 x 103 cell/well in a 96-well plate in triplicate 
and incubated at 37°C, 5% CO2 over the course of 5 days. The MTT assay 
was performed on days 1, 2 and 5 according to the manufacturers 
instructions (Invitrogen-Molecular Probes, Vybrant MTT Cell Proliferation 
Assay Kit). Results are presented as mean +/- S.D. Student’s two-tailed T-
test was performed to determine significance. 
 
Annexin V / Propidium Iodide Apoptosis Analysis 
 Apoptosis analysis was performed according to the manufacturers 
instructions (FITC Annexin V Apoptosis Detection Kit I, BD Pharmingen). 
Briefly, cells were seeded at equal densities in a 25cm2 flask until they 
reached 60-80% confluency. The cells were then washed with cold PBS, 
counted, and normalized to 1x106 cell/ml in 1x Annexin V Binding Buffer. 
Next, 1x105 cells were then transferred to a separate tube and 5µl of FITC 
Annexin V and 5µl of Propidium Iodide were added to each sample. The 
samples were gently vortexed and incubated for 15 min at RT in the dark. 
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Lastly, 400µl of 1x Binding Buffer was added to each sample and the 
samples were analyzed by flow cytometer (Becton Dickinson FACScalibur 
Flowcytometer) with 1 hr. Each sample was performed in triplicate.  
 
Cell Cycle Analysis  
 Cell cycle analysis was measured by flow cytometry (Becton 
Dickinson FACScalibur Flowcytometer) using propidium iodide 
(Invitrogen). BxPC3 and Panc-1 cells were seeded at equal densities in a 
25cm2 flask until they reached 60-80% confluency. Cells were then 
removed from the flask using trypsin (Mediatech Inc.), pelleted and 
washed in cold 1xPBS twice. The cells were counted using a 
hemacytometer and normalized to 1x106 cell/ml in 1xPBS. Cells were 
pelleted and resuspended in equal amounts of RNAse Digestion Buffer 
(2mg/ml of RNAse-A (Sigma) in 1.12% Na-Citrate) and Staining Buffer 
(100ug/mL Propidium Iodide in 0.2% Triton X-100 and 0.1% Na-Citrate). 
The samples were stored on ice and analyzed within one hour of 
collecting. Each sample was performed in triplicate.  
 
RNA Isolation and cDNA Synthesis 
 Total RNA isolation was performed according to the manufactures 
instructions for animal cells using spin technology (RNeasy Mini Kit, 
Qiagen). After RNA was isolated from each sample was reverse 
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transcribed with qScript cDNA Sythesis Kit, Quanta Biosciences according 
to the manufactures instructions.  
 
Quantitative Real Time PCR (qPCR) 
The relative level of GAPDH, QSOX1-L, QSOX1-S, MMP-2, and 
MMP-9 were analyzed in each sample by qPCR. Each cDNA sample was 
normalized to 100ng/µl in molecular grade water along with 100nM final 
concentration of each primer and 1x final concentration of PerfeCta SYBR 
Green Fast Mix, ROX to a final volume of 20µl. qPCR was performed 
using, PerfeCTa SYBR Green FastMix, ROX from Quanta Biosciences on 
a ABI7900HT thermocycler, Applied Biosystems Inc. Reaction Protocol: 
Initial Denaturation – 95oC for 3 min; PCR Cycling (40 cycles) 1.) 95oC, 30 
sec. 2.) 55oC, 30 sec. 3.) 72oC, 1 min; Melt Curve (Dissociation Stage). 
The primer sequences for the genes analyzed are: GAPDH Forward 5’ – 
GGCCTCCAAGGAGTAAGACC; GAPDH Reverse 5’ – 
AGGGGTCTACATGGCAACTG; QSOX1-S Forward 5’ - 
TGGTCTAGCCACAACAGGGTCAAT; QSOX1-S Reverse 5’ - 
TGTGGCAGGCAGAACAAAGTTCAC; QSOX1-L Forward 5’ - 
TTGCTCCTT GTCTGGCCTAGAAGT ; QSOX1-L Reverse 5’ - 
TGTGTCAAAGGAGCTCTCTCTGTCCT  
; MMP-2 Forward  5’ – TTGACGGTAAGGACGGACTC; MMP-2 Reverse 
5’ – ACTTGCAGTACTCCCCATCG; MMP-9 Forward 5’ – 
TTGACAGCGACAAGAAGTGG; MMP-9 Reverse 5’ – 
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CCCTCAGTGAAGCGGTACAT. Each reaction was performed in triplicate 
with the data representing the averages of one experiment.  
 In the shRNA experiment, expression of MMPs was normalized to 
the non-targeted GAPDH to determine ΔCq. ΔCq replicates were then 
exponentially transformed to the ΔCq expression after which they were 
averaged ± standard deviation. The average was then normalized to the 
expression of the shScramble control to obtain the ΔΔCq expression. 
Significance was determined using the student two tailed T-test. 
 
Matrigel and non-Matrigel Coated Invasion Assay 
 Invasion assays were performed using BD BioCoat™ BD 
MatrigelTM as well as non-MatrigelTM control Invasion chambers with 8.0 
µm pore size polyethylene terephthalate (PET) membrane inserts in 24-
well format. The assay was performed according to the manufacturers 
instructions (BD Bioscience). 4 x 104 cells/well were seeded into the inner 
matrigel chamber in serum free DMEM. The outer chamber contained 
10% FBS in DMEM. BxPC3, Panc-1, MCF-7 and BT549 cells were 
incubated for 24 hours (48 hours for BT549 cells) at 370C, 5% CO2. Cells 
that invaded through the Matrigel and migrated through the pores onto the 
bottom of the insert were fixed in 100% methanol and then stained in 
hematoxylin (Invitrogen). The total number of invading cells were 
determined by counting the cells on the underside of the insert from three 
wells (6 fields per insert) at 10x, 20x and 40x magnification and the extent 
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of invasion was expressed as the mean +/- S.D. Significance was 
determined using the Student’s two tailed T-test. Results presented are 
from one of three independent experiments. 
 
Matrigel Invasion Recovery Assay 
 Invasion assays were performed using BD BioCoat™ BD 
MatrigelTM and non-MatrigelTM control Invasion chambers with 8.0 µm pore 
size polyethylene terephthalate (PET) membrane inserts in 24-well format. 
The assay was performed according to the manufacturers instructions (BD 
Bioscience). 4 x 104 cells/well were seeded into the inner matrigel 
chamber in serum free DMEM. The outer chamber contained 10% FBS in 
DMEM. MCF7, BT549, and MDA-MB-231 cells were incubated for 72, 48 
and 24 hours, respectively at 370C, 5% CO2. For invasion rescue assays 
MCF7 and BT549 cells were incubated with 50nM rQSOX1 as well as 
catalytically inactive mutant rQSOX1 (rQSOX1-AA). Cells that invaded 
through the Matrigel and migrated through the pores onto the bottom of 
the insert were fixed in 100% methanol and then stained in hematoxylin 
(Invitrogen). The total number of invading cells were determined by 
counting the cells on the underside of the insert from triplicate wells (6 
fields per insert) at 20x and 40x magnification. The extent of invasion was 
expressed as the mean +/- S.D. Significance was determined using the 
Student’s two tailed T-test. Results presented are from one of three 
independent experiments.  
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Gelatin Zymography 
 The identification of matrix metalloproteinases (MMP) was 
performed using gelatin zymography.  Zymography experiments were 
performed as follows. Untreated BxPC3, Panc-1, MCF-7 and BT549 cells 
as well as shRNA transduced cells were seeded at 5 x 105 cells/well (12 
well plates) in DMEM with 10% FBS.  The next day, cells were then 
washed with 1xPBS and the media was changed to serum free DMEM 
and incubated for 24 hours before collecting the serum free DMEM, 
protein concentration was determined using a BCA assay. Gelatin 
zymography was performed with a 10% polyacrylamide gel containing 
gelatin solution in place of water (0.8 mg/mL Gelatin, 0.15 M Tris pH 8.8, 
30% acrylamide-bis, 50% glycerol, 10% SDS, 10% APS, and TEMED) 
(Snoek-van Beurden and den Hoff). A volume of equal concentrations of 
serum free conditioned media were loaded under non-denaturing 
conditions into the 10% polyacrylamide-gelatin gel to separate proteins 
secreted by the tumor cells and to detect the presence of gelatin 
degrading MMPs (Table 1). Electrophoresis was performed at a constant 
voltage of 150 V for 60 min. Gels were washed in renaturing buffer (25% 
Triton X-100 in water) for 30 min at RT with gentle shaking. The gels were 
then equilibrated in developing buffer (50 mM Tris-base, 6.3 g/L Tris-HCl, 
0.2 M NaCl, 5 mM CaCl2, and 0.02% Triton X-100) for 30 min at RT with 
gentle shaking. Fresh developing buffer was then added to the gels and 
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they were incubated overnight at 370C. The gels were then stained with 
SimplyBlue™ Safe Stain (Invitrogen) for 20 minutes at RT, then destained 
overnight in ddH2O at RT. The presence of MMP was detected by the lack 
of staining indicating digestion of gelatin. The negative control was 
performed by adding, 50 mM Ethylene Diamine Tetra Acetic Acid (EDTA), 
to both the renaturing buffer and the developing buffer to block the MMP 
activation. Quantification of band intensity was measured using Image J 
and is presented as percent change from the scrambled shRNA control.  
 
Conclusion 
 Understanding the role of QSOX1 in normal or tumor cells prior to 
this study was very minimal (Andrade, Stolf, Debbas, Rosa, Kalil, Coelho, 
and Laurindo; Morel et al.; Song et al.). The goal of our initial studies was 
to determine if QSOX1 provided any advantages to tumor cells.  To 
determine if the expression of QSOX1 could be directly linked to the 
hallmark traits of tumors we used loss-of-function studies. Due to the lack 
of background information on the role of QSOX1 we chose establish an in 
vitro model and use broad diagnostic measures to determine if the 
expression of QSOX1 enabled growth, apoptosis, cell cycle regulation and 
invasion.  
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CHAPTER 3 
QUIESCIN SULFHYDRYL OXIDASE 1 (QSOX1) PROMOTES INVASION 
OF PANCREATIC TUMOR CELLS MEDIATED BY MATRIX 
METALLOPROTEINASES. 
Abstract 
We previously mapped a peptide in plasma from pancreatic ductal 
adenocarcinoma (PDA) patients back to an over-expressed QSOX1 
parent protein.  In addition to over-expression in pancreatic cancer cell 
lines, 29 of 37 patients diagnosed with pancreatic ductal adenocarcinoma 
expressed QSOX1 protein in tumor cells, but QSOX1 was not detected in 
normal adjacent tissues or in a transformed, but non-tumorigenic cell line. 
The expression of QSOX1 in tumor cells but not in normal cells suggests 
that QSOX1 provides a functional advantage to tumor cells that is not 
needed in normal cells. Chapter 3 begins to assess the role of QSOX1 in 
tumors by suppressing QSOX1 protein expression using short hairpin 
RNA (shRNA) in 2 pancreatic cancer cell lines, BxPC-3 and Panc-1.  
Tumor cell growth, cell cycle, apoptosis, invasion and MMP activity were 
evaluated.  QSOX1 shRNA suppressed both short and long isoforms of 
the protein showing a significant effect on cell growth, and to a lesser 
extent on cell cycle and apoptosis.  However, QSOX1 shRNA dramatically 
inhibited the abilities of BxPC-3 and Panc-1 pancreatic tumor cells to 
invade through Matrigel in a modified Boyden chamber assay.  
Mechanistically, gelatin zymography indicated that QSOX1 plays an 
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important role in activation of MMP-2 and -9.  Taken together, our results 
suggest that the advantage that QSOX1 provides to tumors is post-
translational activation of MMP-2 and -9. 
Overview 
 Pancreatic ductal adenocarcinoma (PDA) is a disease that carries a 
poor prognosis primarily due to the advanced stage of the disease upon 
diagnosis. There are over 33,000 patients diagnosed with PDA in the 
United States annually and over 80% of those patients present with 
advanced, stage III tumors, and are usually not candidates for surgery at 
the time of diagnosis (Koorstra et al.). However, even if pancreatic cancer 
is surgically resected in stage I or II, it may recur at a metastatic site 
(Bardeesy and DePinho; Almhanna and Philip). Currently, patients 
diagnosed with pancreatic ductal adenocarcinoma have less than a 5% 
chance of surviving past five years due to the late onset of symptoms, the 
highly aggressive nature of PDA and the lack of non-invasive diagnostic 
markers that would allow for early detection (Wong and Lemoine; Koorstra 
et al.).  
Through proteomic analysis of pancreatic cancer patient plasma, 
we discovered a peptide from QSOX1 that maps back to the C-terminus of 
the long isoform of QSOX1 (QSOX1-L) (Figure 1) (Antwi, Hostetter, 
Demeure, Katchman, Decker, Ruiz, Sielaff, Koep, and Lake). 
Subsequently, we found that QSOX1 is over-expressed in tumor tissue 
from pancreatic cancer patients, but not adjacent normal tissue (Figure 2B 
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& C). These findings led us to hypothesize that over-expression of QSOX1 
might be functionally important for tumor cells, prompting further 
exploration of the role that QSOX1 might play in pancreatic cancer. 
 In the present study, we have begun to analyze the biology of 
QSOX1 in tumors using pancreatic tumor cell lines BxPC3 and Panc-1.  
We knocked down QSOX1-S and –L protein expression using shRNA to 
determine if suppression of QSOX1 affected cell growth, cell cycle, 
apoptosis, invasion and MMP activity. QSOX1 knock-downs slowed tumor 
cell proliferation and affected cell cycle and apoptosis.  We also observed 
a dramatic decrease in tumor cell invasion in vitro when QSOX1 
expression was suppressed.  Further investigation into the mechanism of 
invasion revealed that QSOX1 is at least partially responsible for MMP-2 
and MMP-9 activity. This is the first report demonstrating a role for QSOX1 
in invasion and metastasis.  
 
RESULTS 
Detection of QSOX1 by Immunohistochemistry and Western blot 
 To begin to determine the frequency of expression of QSOX1 in 
human PDA, QSOX1 expression was assessed in 4 different pancreatic 
tumor cell lines, an immortal non-tumorigenic cell line, HPDE6, 37 tumor 
tissue sections from patients with PDA, and fresh frozen tumor tissue and 
adjacent normal tissue from two patients, 1016 and 1010 (Figure 2B, C, 
and D). 29 of 37 tumor tissues were positive for QSOX1 expression by 
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immunohistochemistry (IHC), suggesting it is a commonly over-expressed 
protein.  To determine which splice variant was more prevalent in our IHC 
images we analyzed tumor as well as adjacent normal tissue from 2 
patients by western blot (Figure 2C). Our results revealed that QSOX1-S 
is the dominant splice variant expressed in tumor tissue. One of the 
adjacent normal tissue samples (1016) showed a high level of QSOX1 
expression, but it is possible that there was tumor present in the adjacent 
tissue, which would account the increase in QSOX1 expression. Western 
blotting analysis shows that 4 pancreatic tumor cell lines, BxPC3, Panc-1, 
Capan1 and CFPac1 strongly express QSOX1-S and weakly express the 
longer splice variant, QSOX1-L. HPDE6, an immortal, non-tumorigenic 
pancreas epithelial cell line, shows weak expression of QSOX1-S and no 
detectable expression of QSOX1-L (Figure 2D).  
The results of this experiment begin to provide some information 
about the frequency and distribution of QSOX1 expression.   First, QSOX1 
appears to be a commonly over-expressed protein in PDA (Figure 2B & 
C). Second, QSOX1 protein expression in adjacent normal 1010, 1016, 
and HPDE6, a non-tumorigenic pancreatic duct cell line, is weaker than in 
the patient tumor samples and four malignant pancreatic tumor cell lines.  
This may suggest that QSOX1 provides some advantage to malignant 
cells that non-malignant cells do not require.   
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Figure 2: QSOX1 is highly expressed in tumor cell lines but is not 
expressed in adjacent normal cells. Previously, our lab discovered a short 
peptide, NEQEQPLGQWHLS, in patient plasma through LC-MS/MS. We 
were able to map this short, secreted peptide back to an understudied 
parent protein, QSOX1-L. A.) Diagram showing the two splice variants of 
QSOX1, QSOX1-Short (S) and -Long (L), both contains a thioredoxin 
1(Trx1) and ERV/ALR functional domains as well as structural thioredoxin 
2 (Trx2) and helix rich region (HRR). QSOX1-L contains a predicted 
transmembrane (TM) domain. The peptide NEQEQPLGQWHLS, maps 
back to QSOX1-L, and found to be secreted in pancreatic cancer patients 
but not in normal samples. The commercially available antibody 
recognizes the first 329 amino acids of both QSOX1-S and -L. B.) 
Immunohistochemistry of normal (left) and tumor (right) pancreatic tissue 
sections that have been stained with the anti-QSOX1 showing tumor 
specific staining in pancreatic ducts but not in adjacent non-tumor cells. 
C.) Western blot analysis of patient tumor as well as adjacent normal 
tissue indicates that QSOX1-S is the dominant splice variant expressed. 
D.) Western blot showing QSOX1 expression in transformed normal 
pancreatic cells (HPDE6) and Human Pancreatic Adenocarinoma Cells 
(Panc-1, CFPac-1, BxPC3, and Capan1) shows that our in vitro system 
mimics that of the in vivo QSOX1 expression as shown above using IHC.  
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QSOX1 Promotes Tumor Cell Proliferation 
 To examine the advantage that QSOX1 provides to tumor cells we 
inhibited QSOX1 expression in BxPC3 and Panc-1 cells using 3 shRNA 
constructs: sh742, sh528 and sh616. shScrambled was generously 
provided by Dr. Joshua LaBaer.  Lentiviruses containing each shRNA 
were generated as described in “Methods.”  BxPC3 and Panc-1 cells were 
transduced with each sh-lentivirus (shQSOX1) to evaluate the effects of 
QSOX1 knockdown on tumor cell growth.   To demonstrate that the 
shQSOX1 constructs are active in both cell lines, figure 3A and B shows 
reduced protein expression of both isoforms of QSOX1 in BxPC3 and 
Panc-1 tumor cell lines compared to scrambled shRNA in western blot 
analysis.  This experiment demonstrated that sh742, sh528 and sh616 
knock down of QSOX1-S expression in BxPC3 cells was 56%, 40% and 
28%, respectively; for Panc-1 cells the knock down was 64%, 46% and 
18%, respectively (Figure 3A & B).  
ShQSOX1-transduced BxPC3 and Panc-1 cells exhibited a 
decrease in cell growth compared to shScrambled controls in an MTT 
assay (Figure 3C). We seeded an equal number of shScramble, sh742, 
sh528 and sh616 cells in 96 well plates and quantified the proliferation 
rate by measuring mitochondrial metabolism on days 1, 2 and 5. While on  
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Figure 3: Reduced expression of QSOX1 in BxPC3 and Panc-1 cells 
leads to a significant decrease in cell growth. To determine the phenotype 
presented due to the expression of QSOX1 in tumor cells we employed 
shRNA specific to QSOX1 to reduce the expression of QSOX1 in A.) 
BxPC3 (Percent Decrease in sh742 – 56%; sh528 – 40%; sh616 – 28%) 
and B.) Panc-1 (Percent Decrease in sh742 – 64%; sh528 – 46%; sh616 – 
18%) cells and further evaluated cell growth, cell cycle, apoptosis, and 
invasion/metastasis. Western blots have been cropped and full images 
can be viewed in S3. C.) MTT assay on shRNA treated BxPC3 and Panc-
1 cells assayed on day 1, 2, and 5. Data represents averages ± standard 
deviation. Significance *, P <0.05; **, P<0.01.  
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days 1 and 2 there was no change, by day 5 BxPC3 sh742, sh528 and 
sh616 showed a 65%, 60% and 37% decrease, while in Panc-1 sh742, 
sh528 and sh616 there was an 84%, 88% and 61% decrease in cell 
growth as measured by mitochondrial respiration.  
 
Cell Cycle and Apoptosis Analysis 
Previous work has correlated QSOX1 expression with the 
quiescent stage, Go, of the cell cycle (Thorpe et al.).  This led us to 
hypothesize that shQSOX1-mediated decrease in cell proliferation was the 
result of abnormal regulation of the cell cycle or an increase in apoptosis. 
To address this hypothesis, propidium iodide (PI) was used in flow 
cytometry to evaluate the effects of shQSOX1 on cell cycle.  Our results 
indicate that suppression of QSOX1 expression marginally modulated cell 
cycle in both BxPC3 and Panc-1 compared to our untreated and 
scrambled control (Figure 4A & B). The results show that the reduced 
expression of QSOX1 on cell cycle could be cell line dependent. BxPC3 
showed an increase in G1 and a significant decrease in S, while Panc-1 
cells showed a significant decrease in G1 but no changes in S (Figure 4A 
& B). 
 We further evaluated if the decrease in cellular proliferation 
mediated by shQSOX1 was due to an increase in apoptotic cell death. To 
assess apoptosis, BxPC3 and Panc-1 cells transduced with shScramble, 
sh742, sh528 and sh616 were stained with annexin-V and PI (Figure 5).  
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Figure 4: Reduced QSOX1 expression leads to alterations in the cell 
cycle. Cell cycle analysis, using propidium iodide, was performed on A.) 
BxPC3 and B.) Panc-1 cells in which QSOX1 protein expression was 
reduced using shRNA. Plots show representative data sets for gated 
samples of Untreated, Scramble, sh742, sh528 and sh616 from one 
experiment performed in triplicate. The percentages represent the number 
of cells in each stage of the cell cycle G1 (M1), S (M2), and G2/M (M3) 
phase. Data was calculated using Cell Quest Pro. This experiment was 
repeated in triplicate. 
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Figure 5: Reduced expression of QSOX1 in BxPC3 and Panc-1 cells 
leads to an increase in annexin V/ propidium iodide positive cells.  A.) 
Apoptosis Analysis (Annexin V/Propidium Iodide) was performed on 
BxPC3 and Panc-1 cells in which QSOX1 was reduced using shRNA. 
Plots show representative data from one of three individual experiments 
for gated samples of Untreated, Scramble, sh742, sh528 and sh616. The 
percentages represent the number of cells that are annexin V positive 
(Lower Right), annexin V/propidium iodide double positive (Upper Left), or 
propidium iodide positive (Upper Right). Data was calculated using Cell 
Quest Pro software. 
 
 
 
 
 
 
 
  57 
Compared to untreated and shScramble a consistent increase of 2-8% in 
early and late apoptosis (Annexin-V single and double positive) was 
observed for each of the shQSOX1 constructs in BxPC3 and Panc-1 cells. 
Indicating that the reduced expression of QSOX1 does not entirely 
account for the dramatic decrease in cellular proliferation. This data also 
agrees with viable cell counts revealing a largely insignificant decrease in 
shQSOX1 viable cells compared to untreated and shScramble controls.   
 
Role of QSOX1 in Tumor Cell Invasion and Motility 
 For a tumor cell to invade other tissues as part of the metastatic 
process, the cell must first degrade basement membrane components 
such as laminin, collagen and fibronectin before it can migrate into the 
blood stream and re-establish itself in a distant organ (Bacac and 
Stamenkovic). To evaluate whether over-expression of QSOX1 in BxPC3 
and/or Panc-1 cells plays a role in metastasis we performed invasion 
assays over an 18-hour period.  Untreated, shScramble, sh742, sh528 
and sh616-transduced cells were plated in serum-free medium on 
Matrigel-coated, 8µm pore inserts.  Inserts were placed into wells 
containing 10% FBS in DMEM.  After 18 hours of incubation, tumor cells 
that had degraded Matrigel and migrated through 8µm pores onto the 
underside of the insert were counted (Figure 6A & B).  Our results clearly 
demonstrate that knockdown of QSOX1 expression in tumor cells leads to 
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a dramatic decrease in the number of pancreatic tumor cells that degrade 
Matrigel and migrate through the insert into nutrient rich media.  
 To determine if the decrease in the invasive capabilities of BxPC3 
and Panc-1 cells treated with sh742 and sh528 was due to an inability to 
degrade the matrigel allowing for the tumor cells to invade or if the loss of 
QSOX1 leads to a decrease in cellular motility we performed an invasion 
assay using non-Matrigel coated PET membranes containing 8µm pore 
inserts. The untreated, scramble, sh742 and sh528 transduced cells were 
seeded at equal densities in serum free media in the upper chamber. The 
inserts were then placed in wells containing 10% FBS in DMEM. After 24 
hours of incubation, tumor cells that had migrated through 8µm pores onto 
the underside of the insert were counted (Figure 7A & B). Our results 
demonstrate that the loss of QSOX1 significantly affects the motility of 
BxPC3 and Panc-1 cells. While, the decrease in tumor cell motility (non-
Matrigel) strongly suggests that QSOX1 plays a role in cellular motility the 
results in figure 7 do not demonstrate the same dramatic decrease as 
shown with Matrigel (Figure 6) coated inserts suggesting that there are 
further mechanisms that are preventing the tumor cells from degrading the 
Matrigel and migrating to the nutrient rich media.   
 
Mechanism of Invasion 
 Since knock-down of QSOX1 protein expression in pancreatic 
tumor cell lines decreases invasion through Matrigel, it was important to  
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Figure 6: Reduced expression of QSOX1 in BxPC3 and Panc-1 cells 
leads to a significant decrease in in the ability to degrade Matrigel and 
invade into a nutrient rich media. A.) Untreated BxPC3 and B.) Untreated 
Panc-1 cells were treated with Scramble, sh742, sh528 and sh616 
shRNA’s specific for QSOX1 and seeded in the top chamber of Matrigel 
invasion wells and allowed to incubate for 18 hours. Representative 10x, 
20x, and 40x images are presented. In the BxPC3 sh742, sh528 and 
sh616 treated cells there was an 84%, 84%, and 79% decrease in cells 
that were able to break down the basement membrane components of the 
matrigel and invade to the underside of the membrane, repectfully. While 
in Panc-1 sh742, sh528 and sh616 cells there was a 76%, 76%, and 63% 
decrease in cells that were able to degrade the matrigel and invade 
through the membrane. Graphs represent average ± standard deviation 
(BxPC3 n = 6; PANC-1 n = 3), significance *, P < 0.05, **, P <0.005. 
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Figure 7: Reduced expression of QSOX1 in BxPC3 and Panc-1 cells 
leads to a significant decrease in cellular invasion. A.) Untreated BxPC3 
and B.) Untreated Panc-1 cells were treated with Scramble, sh742 and 
sh528 shRNA’s specific for QSOX1 and seeded in the top chamber of a 
non-coated invasion assay well and allowed to incubate for 18 hours. 
Representative 20x images are presented. In the BxPC3 sh742 and sh528 
treated cells there was an 44% and 38% decrease in cells that were able 
to invade to the underside of the membrane, repectfully. While in Panc-1 
sh742 and sh528 cells there was a 75% and 62% decrease in cells that 
were able to invade through the membrane. Graphs represent average ± 
standard deviation (BxPC3 n = 3; Panc-1 n = 3), significance *, P < 0.05, 
**, P <0.005. 
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determine the mechanism of inhibition of the invasive process.  MMP-2 
and -9 are key contributors of invasion and metastasis in pancreatic 
cancer (Bardeesy and DePinho). Both pro-MMP-2 and -9 mRNA and 
protein levels are elevated in pancreatic tumors, and activated MMP-2 (a-
MMP2) appears to be a key contributor of metastasis in PDA (Bardeesy 
and DePinho; Kessenbrock, Plaks, and Werb). Because QSOX1 has been 
suggested to be secreted into the extracellular matrix where MMPs are 
thought to be activated, we hypothesized that QSOX1 might help activate 
MMP-2 and -9 proteins. Untreated BxPC3 and Panc-1 cells, as well as 
transduced shScramble, sh742, sh528 and sh616 were incubated for 18-
24 hours in serum free media after which supernatants were collected and 
subjected to gelatin-SDS-PAGE. Gelatin zymography was performed to 
determine if QSOX1 plays a role in secretion and/or activation of MMPs. 
Our first observation from this experiment is that BxPC3 and Panc-
1 have very different zymographic profiles.  BxPC3 supernatants contain 
MMP-9 homodimer (130kDa), a large amount of proteolytically active pro-
MMP-9 (92kDa) with lesser concentrations of pro-MMP-2 (72kDa) and a-
MMP-2 (66kDa). Panc-1 supernatants contain less prominent MMP-9 
homodimer, pro-MMP-9 (92kDa) and a large amount of proteolytically 
active pro-MMP-2 (72kDa).  
Supernatants from BxPC3 cells transduced with sh742, sh528 and 
sh616 showed a 65%, 47% and 10% decrease, respectively, in pro-MMP9 
compared to shScramble (Figure 8A). Supernatants from Panc-1 cells 
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tranduced with sh742, sh528 and sh616 showed a 70%, 56% and 15% 
decrease, respectively, in pro-MMP-2 (Figure 8B).  Sh616 did not knock 
down QSOX1 as effectively as sh528 and sh742, and this is reflected in 
the cell growth, invasion and MMP activity.   Thus, decreases in the 
proteolytic activity of MMP-2 and -9, using gelatin as a substrate, provide 
a mechanism for the QSOX1-mediated invasion through Matrigel.  
To confirm our gelatin zymography results we used western blot 
analysis of BxPC3 and Panc-1 serum free conditioned media to probe for 
MMP-2 and -9 (Figure 8C). While our results indicate a slight decrease in 
MMP-2 and -9 (between 1-10% decrease using densitometry analysis) in 
BxPC3 and Panc-1 shQSOX1 treated cells it does not reflect the level 
shown using gelatin zymography. This could be explained as a difference 
between a functional assay, gelatin zymography, and a purely quantitative 
assay such as western blot.  
To extend our hypothesis that QSOX1 is influencing MMPs post-
translationally, we performed quantitative real time PCR  (QRTPCR) on 
MMP-2 and MMP-9 comparing the transcripts from shQSOX1 transduced 
cell lines with shScrambled.  Figure 8D demonstrates that MMP-2 and -9 
RNA increased in the shQSOX1 transduced cells compared to control 
cells. This result adds confidence to our hypothesis that QSOX1 does not 
transcriptionally activate MMP production, rather it post-translationally 
activates MMP activity.  It also diminishes the possibility that shQSOX1 
RNAs are suppressing MMP transcription due to off-target effects.   
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Figure 8: Reduced expression of QSOX1 leads to a decrease in secreted 
proMMP-9 in BxPC3 and proMMP-2 in Panc-1 cells. Gelatin zymography 
of A.) BxPC3 and B.) Panc-1 conditioned media showing a decrease in 
MMP-9 homodimers (MMP-9 Complex) (240 and 130 kDa), pro-MMP9 (92 
kDa), pro-MMP2 (72 kDa) and active MMP-2 (a-MMP2, 66 kDa). Using 
Image J we were able to quantitify the percent decrease in proMMP-9 
expression in BxPC3 (Decrease in QSOX1, sh742 – 65%; sh528 – 47%; 
sh616 – 10%) and Panc-1 proMMP-2 (Decrease in QSOX1, sh742 – 70%; 
sh528 – 56%; sh616 – 15%). C.) Western blot analysis of MMP-2 and -9 
on conditioned serum free media from shRNA treated BxPC3 and Panc-1 
cells. Full images can be seen in S3. D.) The effect of shRNA mediated 
knockdown of QSOX1 on the expression of QSOX1-S, QSOX1-L, MMP-2, 
and MMP-9 in BxPC3 and Panc-1 shRNA treated cells was analyzed by 
quantitative real time PCR analysis. The graph represents relative gene 
expression calculated as ΔΔCq using GAPDH as the endogenous 
reference gene.  
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Conclusion 
 The mortality rate for patients diagnosed with pancreatic cancer 
has remained stagnant for the last five decades despite advanced surgical 
procedures and improvements in chemotherapeutics (Koorstra et al.).  
Because most patients present with advanced metastatic disease, it is 
critical to understand the properties of invasive pancreatic tumors. The 
results presented suggest that QSOX1 is a commonly expressed protein 
in PDA making it a potential therapeutic target. To extend these findings 
we began to investigate why pancreatic tumors express QSOX1, and 
mechanistically, what advantage it affords tumors.  
 QSOX1 was previously reported by our group to be over-expressed 
in patients diagnosed with pancreatic cancer (Antwi, Hostetter, Demeure, 
Katchman, Decker, Ruiz, Sielaff, Koep, and Lake), and that a peptide from 
the QSOX1 parent protein is present in plasma from patients with PDA 
(Figure 1). In the present study we demonstrated for the first time that 
expression of QSOX1 in pancreatic tumor cells directly contributes to 
growth (Figure 3C) and an invasive and potentially metastatic phenotype 
(Figure 6 and 7) through the activation of MMP-2 and -9 (Figure 8A & B) 
through an as yet undetermined molecular mechanism.  
The utilities of QSOX1 as a diagnostic and therapeutic target of 
pancreatic cancer remain to be determined. Preliminary IHC of breast, 
lung, prostate and colon cancer suggest that QSOX1 could be a pan 
tumor marker.  If the function of QSOX1 is conserved despite the 
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histological origin of tumor, QSOX1 may be a broad therapeutic target. 
Our results underscore the need to further understand the role that 
QSOX1 plays in tumor and normal cells. Understanding the function of 
QSOX1 in multiple tumor types as well as the substrates in which QSOX1 
interacts with could lead to effective treatment of advanced cancers.  
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CHAPTER 4 
EXPRESSION OF QUIESCIN SULFHYDRYL OXIDASE 1 IS 
ASSOCIATED WITH A HIGHLY INVASIVE PHENOTYPE AND 
CORRELATES WITH A POOR PROGNOSIS IN LUMINAL B BREAST 
CANCER. 
Abstract 
Quiescin sulfhydryl oxidase 1 (QSOX1) oxidizes sulfhydryl groups to form 
disulfide bonds in proteins. Informatic analysis using the “Gene 
Expression Based Outcome for Breast Cancer Online” (GOBO) tool 
indicated high levels of QSOX1 RNA expression in Estrogen Receptor 
positive (ER+) subtypes of breast cancer. We confirmed this finding by 
evaluation of QSOX1 protein expression in breast tumors and in a panel of 
breast cancer cell lines. In addition, Kaplan Meyer analyses revealed 
QSOX1 as a highly significant predictive marker for both relapse-free and 
poor overall survival in Luminal B tumors, but not in other intrinsic 
subtypes. To investigate malignant cell mechanisms in which QSOX1 
might play a key role, we suppressed QSOX1 protein expression using 
short hairpin (sh) RNA in ER+ MCF7 and ER- BT549 breast cancer cell 
lines.  Suppression of QSOX1 protein dramatically slowed cell proliferation 
but did not significantly affect apoptosis or cell cycle regulation.  Inhibition 
of QSOX1 did, however, dramatically inhibit MCF7 and BT549 breast 
tumor cells from invading through Matrigel in a modified Boyden chamber 
assay.  Inhibition of invasion could be rescued by the exogenous addition 
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of recombinant QSOX1. Gelatin zymography indicated that QSOX1 plays 
an important role in activation of MMP-9 a key mediator of breast cancer 
invasive behavior.  Taken together, our results suggest that QSOX1 is a 
novel biomarker for risk of relapse and poor survival in Luminal B breast 
cancer, and has a pro-invasive role in malignant progression through post-
translational activation of MMP-9. 
 
Overview  
 Breast adenocarcinoma is the most common cancer diagnosed in 
women throughout the world (Sgroi). In 2012, an estimated 226,870 new 
cases of invasive breast cancer are expected to occur among US women, 
and an estimated 39,510 breast cancer deaths (Society; Siegel, 
Naishadham, and Jemal). Despite significant advances in subtype 
classification of breast cancers, context-specific drivers of invasion and 
metastasis are still poorly understood. Improvements in screening and 
breast cancer awareness have increased the rate of early diagnosis yet 
the most successful prevention for women with a family history of breast 
cancer still remains to be preventative mastectomy (Talmadge and Fidler). 
The majority of breast tumors have a very slow growth rate, with an 
average doubling time of ±44 days (Talmadge and Fidler). Extrapolating 
this information lets us calculate that on average it takes 12 years for a 
primary tumor to reach 1cm (109 cells) in size, which currently is the 
lowest detectable limit (Talmadge and Fidler). During that time the tumor 
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often develops angiogenic and metastatic capabilities that contribute to a 
poor overall outcome.  
Initially we reported the identification of a short peptide that maps 
back to the C-terminus of QSOX1 in plasma from pancreatic cancer 
patients (Antwi, Hostetter, Demeure, Katchman, Decker, Ruiz, Sielaff, 
Koep, and Lake). Subsequently, we found that QSOX1 is over-expressed 
in tumor tissue from pancreatic cancer patients, but not adjacent normal 
tissue (Katchman, Antwi, Hostetter, Demeure, Watanabe, Decker, Miller, 
Hoff, and Lake). To determine if QSOX1 is overexpressed in other tumor 
types we performed IHC on breast tissue microarrays and discovered that 
the expression of QSOX1 is specific to dysplastic cells as well. These 
findings led us to hypothesize that over-expression of QSOX1 might be 
functionally conserved between pancreatic ductal adenocarcinoma and 
breast adenocarcinoma, prompting further exploration of the function of 
QSOX1 as it relates to cancer (Hanahan and Weinberg). 
 In the current chapter we evaluated QSOX1 protein expression in 
breast adenocarcinoma cell lines MCF7 and BT549 and in a breast tumor 
tissue microarray. Using shRNA specific for QSOX1-S and –L, we 
assessed the effects of QSOX1 knockdown on cell growth, cell cycle, 
apoptosis, invasion and matrix metalloproteinase activity. The loss of 
QSOX1 significantly affected tumor cell proliferation and dramatically 
suppressed tumor cell invasion through Matrigel while the addition of 
exogenous catalytically active recombinant human QSOX1 (rhQSOX1) 
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rescued the invasive properties of both MCF7 and BT549 transduced with 
a lentivirus encoding shQSOX1.  Further investigation into the mechanism 
of invasion revealed that QSOX1 is at least partially responsible for MMP-
9 activity.  
  
RESULTS 
Expression of QSOX1 correlates with poor prognosis in patients with 
Luminal B breast cancer.  
Bioinformatic analysis of QSOX1 transcript expression was 
assessed using data from the Gene expression based Outcome for Breast 
cancer Online algorithm (GOBO) (Ringnér, Fredlund, Häkkinen, Borg, and 
Staaf). GOBO analysis utilizes Affymetrics gene expression data curated 
from 1881 breast cancer patients with associated stage, grade, nodal 
status and intrinsic molecular classification based on the paradigm first 
reported by the Perou laboratory (Sørlie et al.). Expression of QSOX1 was 
significantly higher in ER+ tumors compared to ER- (p-value <0.00001), 
with the highest expression observed in Luminal A, Luminal B and Normal 
like subtypes, and lowest expression in HER2-enriched and basal-like 
tumors (Figure 9A & B).  We performed a series of Kaplan Meier analyses 
to determine whether QSOX1 expression is associated with relapse free 
survival (RFS) and overall survival (OS) (Figure 9C & D). The results of 
these statistically significant analyses are summarized in Table 1.  While 
elevated QSOX1 expression is not associated with survival when  
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Figure 9. GOBO analyses of QSOX1 transcript expression among 
subtypes of breast cancer from over 1800 cases. a) Box plot analysis of 
QSOX1 mRNA expression in all tumors ER+ (n=1225) and ER- tumors 
(n=395) (p= <0.00001); b) Box plot analyses of QSOX1 expression among 
HU subtypes, Basal (n=357), HER2 (n=152), Luminal A (n=482), Luminal 
B (n=289), Normal-like (n=257) and untreated (n=344), (p= <0.00001). c) 
Kaplan Meier analysis of relapse free survival (RFS) in patients with 
Luminal B breast cancer expressing high (red line) and low (grey line) 
QSOX1 mRNA; High (n=56), low (n=74), (p=0.00062) and d) Overall 
survival (OS); High (n=34), low (n=64), (p=0.00031). Data obtained using 
GOBO: Gene expression based outcome for breast cancer online 
(http://co.bmc.lu.se/gobo). 
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RFS      
(p-value) 
Low 
 (n) 
High 
 (n) 
OS       
(p-value) 
Low  
(n) 
High  
(n) 
All tumors 0.86755 477 437 *0.09682 424 313 
ER+ 0.35126 354 384 *0.02481 287 283 
ER- 0.76167 120 46 0.46447 137 36 
Luminal A 0.77820 84 177 *0.02507 62 127 
Luminal B *0.00062 74 56 *0.00031 64 34 
HER2 0.77143 44 27 0.73943 39 21 
Normal 
Like 0.10710 68 111 0.45693 50 77 
Basal-like 0.82086 113 30 0.50018 123 23 
Grade1 0.16030 60 130 0.19165 51 88 
Grade 2 0.50226 207 204 *0.04242 163 152 
Grade 3 0.30450 178 79 0.07095 197 65 
Untreated 0.45345 261 156 *0.00109 216 91 
 
 
 
Table 1 Summary of the statistical analysis from GOBO: Gene Expression 
Based Outcome for Breast Cancer Online of mRNA expression for 
QSOX1 in breast cancer subtypes using relapse free survival (RFS) and 
overall survival (OS) as an endpoint. Each subtype was separated into two 
groups based on the mRNA expression levels of QSOX1. High and low 
refers to patients with low QSOX1 expression of mRNA ranging from (-
3.8218, 0.0221) and patients with high levels of QSOX1 mRNA ranging 
from (0.0221, 3.1337) while n refers to the total number of patients 
sampled within the subtype indicated. A two-tailed ttest was performed to 
determine the statistical significance of QSOX1 expression within each 
individual subtype, expressed as the p-value.  
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considering all breast tumor subtypes together (Table 1), it is highly 
statistically associated with poor RFS (p=0.00062) and OS (p=0.00031) in 
Luminal B tumors (Figure 9C & D; Table 1).  Elevated QSOX1 was also 
associated with reduced OS in luminal A tumors and is a poor predictor of 
OS for patients who did not receive systemic treatment (Table 1).  
 
Evaluation of QSOX1 expression by Immunohistochemistry  
Results from the GOBO transcript expression analysis fueled 
investigation of QSOX1 at the protein level in breast tumors. A breast 
tumor tissue microarray composed of breast tumors from over 150 
different patients was stained with a rabbit anti-QSOX1 polyclonal 
antibody and scored by a board certified pathologist (I.T.O.).  Figures 10A 
and B represent the pattern of QSOX1 expression observed in the TMA in 
an invasive ductal carcinoma (Figure 10A) and an invasive lobular 
carcinoma (Figure 10B). Statistical evaluation of QSOX1 expression by 
immunohistochemistry (IHC) demonstrated a strong association of ER+ 
tumors with a higher QSOX1 IHC score (Table 2), with no statistical 
association observed for QSOX1 expression and HER2+ tumors or 
cytokeratin markers of the basal-like subtype. This data is consistent with 
the correlation observed in the GOBO data. Interestingly, higher-grade 
tumors were associated with a higher QSOX1 IHC score (Table 2).  
Conversely, lower QSOX1 protein expression was significantly associated  
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Figure 10. Protein expression of QSOX1 is specific for breast tumor cells 
in tissue (a, b) Immunohistochemistry of breast tumor tissue microarray 
samples showing positive staining for QSOX1 in tumor samples: a) 
invasive ductal carcinoma, ER+, PR+; b) invasive lobular carcinoma, ER+, 
PR-. Polyclonal antibody recognizes residues 1-329 of both QSOX1-S and 
–L.  c) Western blot showing weak expression of QSOX1 in transformed, 
but non-tumor-forming MCF10A and human breast ductal carcinoma cell 
lines MCF7, MDA-MB-468, MDA-MB-453, BT549 and MDA-MB-231. β-
actin loading control is shown below each lane. 
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IHC score 
p-
value 
 
0 (n=17) 
% 
11/12/21 
(n=47) 
% 
13/22/31 
(n=24) 
% 
23/33/32 
(n=65) 
%   
Grade   
  
  *0.0003 
1 53.3 42.2 25.0 10.8 
 2 33.3 33.3 41.7 32.3 
 3 13.3 24.4 33.3 56.9 
 ER         *0.0013 
+ 80.0 89.1 73.9 55.4 
 - 20.0 10.9 26.1 44.6   
HER2   
  
  0.0811 
Positive/equivocal 11.8 6.4 29.2 14.1 
 Negative 88.2 93.6 70.8 85.9 
 CK5/6         0.0733 
0 100.0 95.7 87.5 83.1 
 1/2/3 0.0 4.3 12.5 17.0   
ER & HER2         *0.0016 
ER -. HER2 
- 13.3 8.7 8.7 35.9 
 Others 86.7 91.3 91.3 64.1   
ER, HER2 & CK5/6   
  
  0.0923 
ER -. HER2 
-, CK5/6: 1/2/3 0.0 4.3 4.2 15.4 
 Others 100.0 95.7 95.8 84.6   
 
Table 2 Statistical assessment of QSOX1 protein expression with 
molecular subtypes of breast cancer. QSOX1 expression was grouped 
into 4 categories based on the percentage of cells stained and the 
intensity of QSOX1 expression: 0: no expression, 11/12/21: weak, 
22/13/31: moderate and 32/33/23: strong (see material and methods for 
detailed explanation). Each number represents the percentage of QSOX1 
positive or negative cells within each molecular subtype of breast cancer 
(n=total number of tissue samples within each category). Pearson’s chi-
square test was performed to determine a relationship between the 
molecular subtypes and QSOX1 expression. Statistical significance using 
a 2-sided P value was set at P ≤ 0.05*. 
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with lower grade tumors. This is consistent with an association between 
QSOX1 expression and more aggressive ER+ tumors.  While we do not 
have intrinsic subtype subclassification, relapse or survival data for the 
TMA tumors, it will be of interest to determine whether the ER+ tumors 
with elevated QSOX1 have a high proliferative index (Ki67 immunostain), 
and exhibit a relatively low percentage level of Progesterone Receptor 
positivity, suggestive of a Luminal B tumor. 
 
Evaluation of QSOX1 expression by Western blot 
QSOX1 expression in human breast adenocarcinoma was 
assessed in 5 different breast tumor cell lines, and a transformed non-
tumorigenic breast cell line, MCF10A (Blick, Widodo, Hugo, Waltham, 
Lenburg, Neve, and E. W. Thompson). Consistent with our previous 
studies in pancreas cancer (Katchman, Antwi, Hostetter, Demeure, 
Watanabe, Decker, Miller, Hoff, and Lake), the short form of QSOX1 is 
expressed as the predominant splice variant in each cell line examined 
(Figure 10C).  Consistent with the GOBO and IHC expression data, we 
found that the expression of QSOX1-S protein was more highly expressed 
in luminal-like cell lines MCF7 (ER+), MDA-MB-468 (ER-) and MDA-MB-
453 (ER-) compared to basal-like BT549 and MDA-MB-231 cell lines.  
Interestingly, QSOX1 was most weakly expressed in MCF10A which does 
not form tumors in immunodeficient animals. 
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Expression of QSOX 1 in tumor cells promotes cellular proliferation 
 To begin to assess the mechanistic role that QSOX1 plays in tumor 
cells we stably knocked-down QSOX1 expression in MCF7 and BT549 
cells using two lentiviral shRNA constructs, sh742 and sh528 (Figure 
11A). QSOX1 protein expression was assessed following stable knock-
down relative to isogenic parental cell lines by western blotting.  
Densitometry of the QSOX1 protein indicates that sh742 and sh528 
resulted in a knock-down of QSOX1-S expression in MCF7 cells by 85% 
and 82% respectively; for BT549 cells the knock-down was 65% and 77%, 
respectively (Figure 11A).  
The growth rates of shQSOX1-transduced MCF7 and BT549 cells 
were then evaluated compared to isogenic controls (Figure 11B). We 
seeded an equal number of untransduced (parental), shScramble, sh742 
and sh528 cells in 96 well plates and assayed for proliferation over 5 days 
using the MTT assay. ShQSOX1-transduced MCF7 and BT549 cells both 
displayed a decrease in cell growth compared to shScrambled and 
parental controls (Figure 11B). In MCF7, sh742 and sh528 showed a 66% 
decrease in cell growth, while sh742 and sh528 suppressed growth of 
BT549 by 78% and 69%, respectively by day 5. Microscopically, we did 
not observe any morphological changes associated with loss of QSOX1 
expression in either cell line. 
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Figure 11. Reduced expression of QSOX1 leads to a significant decrease 
in tumor cell growth. MCF7 and BT549 breast tumor cell lines were 
transduced wtih lentiviral shRNA QSOX1 (sh742 and sh528). a) Western 
blots are shown using the same anti-QSOX1 polyclonal Ab as in figure 2 
on cell lysates from MCF7 (percent decrease in sh742: 85% and sh528: 
82%) and BT549 (percent decrease in sh742: 45% and sh528: 77%) cells. 
Western blots have been cropped and full images can be viewed in 
Supplementary Fig. S3. (b) MTT assay on MCF7 and BT549 cells 
transduced with shScramble, sh742 and sh528 assayed on Days 1 
through 5. Percent decrease sh742 and sh528 day 5: 66%; percent 
decrease sh742 and sh528 on day5: 78% and 69%, respectively. 
Experiment was performed three times in triplicate; error bars represent 
SD from triplicate wells. Significance **, P= < 0.01. 
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Cell Cycle, Apoptosis and Autophagy Analysis 
In non-tumor fibroblasts, expression of QSOX1 was correlated with 
the quiescent stage, Go, of the cell cycle and overexpression of QSOX1 
was shown to protect MCF7 cells for ROS mediated apoptosis (Morel et 
al.). This led us to hypothesize that a shQSOX1-mediated decrease in cell  
proliferation could be the result of abnormal regulation of the cell cycle, an 
increase in apoptosis or the result of autophagosome formation. To 
address this, propidium iodide (PI) was used in flow cytometry to evaluate 
the effects of shQSOX1 on cell cycle.  In MCF7 cells, both shQSOX1 
RNAs showed a slight decrease in G1 and an increase (11-12%) in S 
phase, but neither shQSOX1 RNA sequence had any effect in BT549 cells 
compared to untreated and shScramble controls (Figure 12A & B).  
  Next we determined if the decrease in cellular proliferation was due 
to an increase in apoptosis or autophagy (Figure 12C & D). To assess 
apoptosis, we analyzed MCF7 transduced cells for Annexin V/ PI and 
BT549 transduced cells for increased expression of Caspase 3 (Plati, 
Bucur, and Khosravi-Far). We subsequently probed MCF7 and BT549 
transduced cells for LC3, a protein that is necessary for auotphagosome 
formation (Chen and Klionsky). If the expression of QSOX1 prevented 
cellular apoptosis or autophagy we would expect to see an increase in 
expression of Annexin V, Caspase 3 and LC3 in shQSOX1 transduced 
cells, but we did not observe any changes (Figure 12A & B). This  
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Figure 12. Suppression of QSOX1 in MCF7 and BT549 cells does not 
lead to an increase in apoptosis or autophagy. a) MCF7 and b) BT549 
cells treated with shRNAs were analyzed for deviations in the cell cycle. 
Analysis was performed using propidium iodide to label DNA and analyze 
cells in G1, S and G2/M of the cell cycle by flow cytometry. Annexin V/ 
Propidium Iodide analysis was performed on c) MCF7 cells to assess 
apoptosis. Western blot analysis of a) MCF7 and BT549 untreated, 
shScramble, sh742 and sh528 total cellular protein probed for Caspase3 
or LC3. BT549 cells incubated exogenously with 50uM H2O2 to induce 
expression of Caspase 3 (apoptosis) and LC3 (autophagy) is used as a 
positive control. 
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correlates with our previous results in pancreas cancer that the 
suppression of QSOX1 does not lead to cell death or autophagy.  
 
Suppression QSOX1 expression inhibits tumor cell invasion 
 The process of tumor cell invasion involves the degradation of 
basement membrane components such as laminin, collagen and  
fibronectin before a tumor cell is able to invade other tissues (Bacac and 
Stamenkovic). We performed a modified Boyden chamber assay using 
Matrigel-coated inserts in which tumor cells must degrade the Matrigel and 
migrate through a membrane with 8um pores to gain access to nutrient 
rich media. Sh742 and sh528-transduced MCF-7 and BT549 tumor cells 
were added to Matrigel-coated, 8um pore inserts in serum-free medium. 
After 72 (MCF7) and 48 (BT549) hours of incubation, tumor cells that were 
able to degrade Matrigel and migrate through 8um pores onto the 
underside of the insert were counted (Figure 13A & B).  Our results 
demonstrate that knockdown of QSOX1 expression in MCF7 leads to a 
65% and 71% reduction in invasion of sh742 and sh528 transduced tumor 
cells, respectively. A 60% and 40% decrease in invasion through Matrigel 
for sh742 and sh528 BT549-transduced tumor cells was observed.  
 To prove that suppression of QSOX1 protein expression was 
responsible for loss of tumor cell invasion, we performed a rescue 
experiment in which we added exogenous recombinant human QSOX1 
(rhQSOX1, generously provided by Dr. Colin Thorpe) to shQSOX1-MCF7 
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and shQSOX1-BT549.  As a control for the enzymatically active QSOX1, a 
mutant rhQSOX1 in which the CxxC motif in the thiredoxin-1 domain was 
mutated to AxxA (rhQSOX1(AA), generously provided by Dr. Debbie 
Fass). Addition of enzymatically active rhQSOX1 rescued the invasive 
properties of both shQSOX1-MCF7 (Figure 13C) and shQSOX1-BT549 
(Figure 13D) sh742 cells to the level of the shScramble control, while the 
addition of the rhQSOX1(AA) did not rescue invasion of tumor cells 
transduced with shQSOX1.   
 To determine if the decrease in the invasive capabilities of MCF7 
and BT549 cells treated with sh742 and sh528 was due to an inability to 
degrade the matrigel allowing for the tumor cells to invade or if the loss of 
QSOX1 leads to a decrease in cellular motility. We performed an invasion 
assay using non-Matrigel coated PET membranes containing 8µm pore 
inserts. Both cell lines MCF7 and BT549 untreated, scramble, sh742 and 
sh528 transduced cells were seeded at equal densities in serum free 
media in the upper chamber. The inserts were then placed in wells 
containing 10% FBS in DMEM. After 24 hours of incubation, tumor cells 
that had migrated through 8µm pores onto the underside of the insert were 
counted (Figure 14A & B). Our results demonstrate that the loss of 
QSOX1 significantly affects the motility of MCF7 and BT549 cells. While 
the decrease in cellular motility (non-Matrigel) strongly suggests that 
QSOX1 plays a role in cellular movement we wanted to further determine  
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Figure 13. QSOX1 promotes tumor cell invasion in breast tumor cells. a) 
MCF7 and b) BT549 cells transduced with shSramble, sh742 and sh528 
shRNAs were seeded at equal densities in the top chamber of Matrigel 
invasion wells and allowed to incubate for 48 (BT549) and 72 (MCF7) 
hours, after which cells that had digested Matrigel and migrated through 
the 8um pores were counted on the underside of the insert. 
Representative 20x and 40x images are presented. For MCF7 cells 
transduced with sh742 and sh528 there was a 65% and 71% decrease in 
invasion compared to shScramble controls, respectively.  For BT549 cell 
transduced with sh742 and sh528 there was a 60% and 40% decrease in 
invasion. The invasive phenotype of shQSOX-transduced c) MCF7 and d) 
BT549 cells was rescued by exogenous incubation with catalytically active 
rhQSOX1. rhQSOX1 (AA) mutant is a mutant without enzymatic activity, 
generously provided by Dr. Debbie Fass. Graphs represent average ± SD 
(MCF7 and BT549 n=3), significance *, P < 0.05, ** P < 0.005.   
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Figure 14. Reduced expression of QSOX1 in MCF7 and BT549 cells 
leads to a significant decrease in cellular invasion. A.) Untreated MCF7 
and B.) Untreated BT549 cells were treated with Scramble, sh742 and 
sh528 shRNA’s specific for QSOX1 and seeded in the top chamber of a 
non-coated invasion assay well and allowed to incubate for 24 hours. 
Representative 20x images are presented. In the MCF7 sh742 and sh528 
treated cells there was a 44% and 38% decrease in cells that were able to 
invade to the underside of the membrane, respectfully. While in BT549 
sh742 and sh528 cells there was a 75% and 62% decrease in cells that 
were able to invade through the membrane. Graphs represent average ± 
standard deviation (MCF7 n = 3; BT549 n = 3), significance *, P < 0.05, **, 
P <0.005. 
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if the loss of QSOX1 in breast tumor cells also contributes to a decrease in 
protease function. 
 
Decrease in QSOX1 leads to a decrease in Matrix metalloproteinase 
activity  
 Since knockdown of QSOX1 resulted in decreased breast tumor 
cell invasion, it was important to determine a mechanism. Matrix  
metalloproteinases (MMP) have been shown to play key roles in breast 
tumor invasion and metastasis (E. S. Radisky and D. C. Radisky). Both 
MMP-2 and -9 mRNA and protein levels have been shown to contribute to 
breast tumor invasion, metastasis and angiogenesis (E. S. Radisky and D. 
C. Radisky). Since previous work demonstrated that QSOX1-S is secreted 
into the extracellular matrix where MMPs are activated, we hypothesized 
that QSOX1 might help activate MMP-2 and -9 proteins. MCF7 and BT549 
cells transduced with shScramble, sh742 and sh528 were plated at equal 
densities and allowed to incubate in serum free media for 48 hours, after 
which the supernatants were collected and analyzed by gelatin 
zymography to determine if the loss of QSOX1 leads to a decrease in the 
functional activity of MMP-2 and -9. 
Initial analysis of the results indicate that MCF7 and BT549 
possess similar MMP profiles even though it is known that BT549 cells are 
more invasive.  Both MCF7 and BT549 supernatants contain MMP-9 
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homodimer (130kDa), a large amount of proteolytically active pro-MMP-9 
(92kDa) with lesser concentrations of pro-MMP-2 (72kDa).  
We found that supernatants from MCF7 cells transduced with 
sh742 and sh528 showed a 70% and 77% decrease, respectively, in pro-
MMP9 activity compared to shScramble (Figure 15A). Supernatants from 
BT549 cells transduced with sh742 and sh528 showed a 34% and 88% 
decrease, respectively, in pro-MMP-9 (Figure 15B). Decreases in the 
proteolytic activity of MMP-9, using gelatin as a substrate, provide a 
mechanism for the shQSOX1-mediated suppression of invasion through 
Matrigel.  
To extend our hypothesis that QSOX1 is activating MMPs post-
translationally, we performed a Western blot on MCF7 and BT549 total 
cellular lysate as well as quantitative real time PCR (qPCR) to determine if 
the loss of QSOX1 affected MMP protein and RNA levels (Figure 15C and 
D). Our results indicate that the secreted amount of MMP-2 and -9 protein 
is similar between the untreated, shScramble, sh742 and sh528 samples 
in both MCF7 and BT549 cells (Figure 15C). Figure 15D demonstrates 
that the loss of QSOX1 also has no significant effect on the transcription of 
MMP-2 and -9. These results add confidence to our hypothesis that 
QSOX1 post-translationally activates MMPs.  
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Conclusion 
In this study we show, for the first time that QSOX1 over-
expression is associated with features of poor prognosis in breast cancer 
patients whose tumors express QSOX1. We also demonstrate the 
prognostic power of QSOX1 at the RNA and protein level. Analysis using 
GOBO of over 1800 breast cancer patients revealed that QSOX1 
expression in luminal B breast cancer correlates with very poor RFS and 
OS (Figure 9C and D). Additionally, expression of QSOX1 mRNA in the 
GOBO analysis and IHC correlate with higher-grade tumors in our breast 
tumor TMA analysis (Table 2). Importantly, in patients who did not receive 
systemic therapy (presumably due to diagnosis of very early stage 
disease), QSOX1 appears to be a predictor of poor OS (Table 1). These 
data collectively suggest that QSOX1 is associated with bad-acting ER+ 
tumors and warrants further preclinical and prospective validation as a 
prognostic biomarker of ER+ tumors.  
Our in vitro data suggest that QSOX1 has a conserved function in 
tumor cells regardless of the primary cell source. Tumor cells in which 
QSOX1 expression was suppressed using shRNAs grew at less than half 
the rate of shScramble and untreated controls in both MCF7 and BT549 
cells (Figure 11B). While QSOX1 does not appear to play a role in cell 
cycle regulation, apoptosis or autophagy the loss of QSOX1 led to a 
dramatic decrease in both MCF7 and BT549 cells ability to degrade 
Matrigel and invade into a nutrient rich medium (Figure 13A and B). 
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Expression of QSOX1 promotes breast tumor growth and invasion in vitro, 
mediated mechanistically by post-translational activation of MMP-9 
functional activity (Figure 15A and B). While further research is still 
needed to understand the role of QSOX1 in vivo the results presented 
here strongly suggest that targeted inhibition of QSOX1 may stall cancer 
progression.  
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Figure 15. Reduced expression of QSOX1 in MCF7 and BT549 cells 
leads to a decrease in functional MMP-9 activity. Gelatin zymography of a) 
MCF7 and b) BT549 conditioned media shows a decrease in MMP-9 
homodimers (130 kDa) and MMP-9 (92 kDa). The percent decrease in 
MMP-9 expression in MCF7 was:  sh742: 70%; sh528: 77%, and in BT549 
was: sh742: 34%; sh528: 88% compared to shScramble control. c) 
Western blots of total cellular lysate from shRNA treated MCF7 and 
BT549 probing for MMP-2 and -9.  Percent decrease of MCF7 (sh742: 
26%; sh528: 20%) and BT549 (sh742: 26% ; sh528: 78%) compared to 
shScramble control. Full images can be seen in Supplementary Fig. S3.  
d) QPCR of QSOX1 transcripts and MMP-2 and -9 transcripts. The graph 
represents relative gene expression calculated as ΔΔCq using GAPDH as 
the endogenous reference gene. 
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CHAPTER 5 
DISCUSSION AND CONCLUSION 
 
 The discovery and subsequent study of factors that contribute to 
tumor cell growth and invasion provide an opportunity to develop targeted 
therapeutics that could be used alone or in combination with other anti-
neoplastic agents. The ability to effectively treat and cure patients with 
advanced metastatic tumors will be the turning point in cancer therapy. 
Prior to our discovery of a short peptide secreted in patient plasma, it was 
not previously known that QSOX1 was over-expressed in pancreatic 
tumors (Antwi, Hostetter, Demeure, Katchman, Decker, Ruiz, Sielaff, 
Koep, and Lake). The results presented within this thesis suggest that 
QSOX1 is a commonly over-expressed protein in PDA as well as breast 
adenocarcinoma making it a potential therapeutic and diagnostic target. 
To extend these initial findings we began to investigate why pancreatic 
and breast tumors over-express QSOX1, and mechanistically, what 
advantage it affords tumors. 
To determine if QSOX1 was also over-expressed in breast cancer, 
a GOBO analysis was performed using data from over 1800 breast cancer 
cases (Ringnér, Fredlund, Häkkinen, Borg, and Staaf). GOBO is an open 
source software program that allows one to analyze the expression of 
specific genes from over 1800 breast tumor samples and 51 cell lines 
using data generated with Affimetrix U133A microarrays. We correlated 
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our GOBO analysis data with IHC analysis of tumor tissue samples 
probed for QSOX1, ER +/-, HER2, and CK5/6 (Table 2). We found a very 
strong correlation between the RNA expression of QSOX1 found in the 
GOBO analysis and our IHC results from breast TMAs. A prominent 
finding in this analysis is that the highest levels of QSOX1 expression in 
luminal B breast cancer correlate with very poor RFS and OS (Figure 9C 
& D), the median survival in patients with luminal B breast cancer who 
over-express QSOX1 is ~4 years. The prognostic power of QSOX1 
expression for RFS and OS increases when luminal B breast cancer 
cases are divided into quintiles using the GOBO analysis tool for which 
patients with the highest fifth expression of QSOX1 have RFS of less than 
2 years and OS of less than 3 years.  Additionally, expression of QSOX1 
mRNA in the GOBO analysis and protein in IHC correlate with luminal 
tumors and higher-grade tumors in our breast tumor TMA analyses (Table 
1 and 2). Expression of QSOX1 did not correlate with survival in HER2 
enriched tumors, ER- tumors, or in tumors subtyped as basal-like.  
Importantly, in patients who did not receive systemic therapy (presumably 
due to diagnosis of very early stage disease), QSOX1 appears to be a 
predictor of poor OS (Table 1).  However, this association was not strong 
until more than 5 years post diagnosis. Collectively this suggests that 
QSOX1 is associated with bad-acting ER+ and further analysis will also 
need to be done to correlate QSOX1 protein expression with OS and RFS 
in luminal B tumors using Ki-67 as a marker of proliferation.  
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To determine what advantages QSOX1 provided to tumor cells we 
inhibited QSOX1 using shRNAs. The shRNAs specific to QSOX1 were 
packaged into lentivirus allowing us to generate stable pancreatic and 
breast tumor cell lines. The application of lentiviral transduction of shRNAs 
over transient tranfection of siRNA/shRNA allowed us to improve our 
percent knock-down of QSOX1 as well as providing us with highly 
reproducible results. As discussed in the introduction one of the first 
hallmarks of cancer is the ability of a tumor cell to proliferate 
uncontrollably. Tumor cells, both pancreatic and breast cells, in which 
QSOX1 protein expression was suppressed by shQSOX1 grew more 
slowly over time than the shScrambled and untreated controls as 
measured by an MTT assay (Figure 3C and 11B). We evaluated the 
growth of both pancreatic and breast tumor cells over a five day period 
and observed greater than 50% decrease in cell growth in all cell lines 
tested to date.  
Our attempt to explain the decrease in cell growth as an alteration 
in cell cycle regulation, increase in apoptosis or autophagy failed to 
demonstrate changes that could explain our MTT results (Figure 4, 5, and 
12). Contrary to previous statements implicating QSOX1 as a cell cycle 
regulator (Coppock, Cina-Poppe, and Gilleran), our results suggest that 
while the loss of QSOX1 in Panc-1 and MCF7 (luminal-like) cells shows a 
minor, but consistent stall in G1, BxPC3 and BT549 (basal-like) cells do 
not follow this cell cycle example. This suggests that the role of QSOX1 in 
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cell cycle regulation could be cell type and tumor stage dependent (Figure 
4 and 12). Combined, these results from two different tumor types suggest 
that cell cycle is not an important feature in the tumor biology of QSOX1. 
Early experiments by Donald Coppock found that QSOX1 is 
secreted from WI-38 lung fibroblast cells as the cells become confluent 
and entered into a quiescent state. These experiments suggested that 
QSOX1 was involved in the transition from G0 to G1 in the cell cycle 
although this hypothesis was never validated (Coppock, Cina-Poppe, and 
Gilleran). While our experiments suggest that in specific tumor types 
QSOX1 may influence the cell cycle regulation they do not suggest that 
QSOX1 is an essential protein involved in transitioning cells from one 
stage in the cell cycle to the next.  Another factor comparing early QSOX1 
experiments with our results is cell type.  WI-38 cells are non-tumor lung 
fibroblasts whereas our work was done with human malignant tumor cell 
lines. 
Our analysis of apoptosis and autophagy as a second possible 
mechanism contributing to the observed decrease in cell growth did not 
reveal significant increases in Annexin V/ propidium iodide, Caspase 3 or 
LC3 (marker for autophagosome formation). In both pancreatic and breast 
tumor cells we failed to show significant increases in annexin V/ propidium 
iodide double positive cells as well as caspase 3 expression (BxPC3 - 8%; 
Panc-1 – 1.5%; MCF7 – 2%; BT549 – no increase in Caspase 3) (Figure 5 
and 12). At this time, it is not known why or how QSOX1 drives growth of 
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tumor cells.   However, the discovery that the loss of QSOX1 leads to a 
decrease in MMP activity could provide a possible explanation as to our 
observed decrease in growth. As MMPs cleave BM components they 
release growth factors, cytokines and chemokines that bind to receptor 
tyrosine kinases and promote cell growth. Within the same context the 
cleavage of different BM proteins also provides binding sites for integrin 
receptors that drive growth as well as promote cellular motility and 
invasion (E. S. Radisky and D. C. Radisky). Thus the loss in MMP 
functional activity could lead to a decrease in the availability of growth 
factors providing a possible explanation for the consistent decrease in cell 
growth observed in all of the cell lines tested. 
There are numerous proteins within the cell that assist in disulfide 
bond formation that may compensate for the loss of QSOX1 such as 
protein disulfide isomerase (PDI), thioredoxin, glutathione and members of 
the Erv family of sulfhydryl oxidases (Fass). Currently there are no known 
preferred substrates of QSOX1 although speculation based on the 
function of QSOX1 as well as the known substrates that correspond to 
QSOX1 functional domains, leads us to believe that there are a broad 
spectrum of possible substrates and therefore the role that QSOX1 plays 
in tumor cell progression would most likely be influenced by the substrates 
with the greatest affinity for QSOX1. Compensation by other sulfhydryl 
oxidases could help explain why the loss of QSOX1 does not lead to 
significant alterations in the cell cycle and apoptosis.  
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Because QSOX1 appears to be involved in tumor cell proliferation 
and to some extent, viability, the activity of QSOX1 in tumor cells is 
certainly not limited to post-translational activation of MMPs.  QSOX1 may 
play a role in many cellular functions such as formation and maintenance 
of the ECM.  Microscopic examination of shQSOX1-transduced tumor 
cells compared to shScrambled-transduced tumor cells demonstrated 
more detached and rounded cells in the shQSOX1 transduced cells.  
Furthermore preliminary data from The Fass lab at The Weizmann 
Institute suggest that loss of QSOX1 significantly alters the expression 
and secretion of basement membrane proteins such as lamanin (Personal 
Communication). Basement membrane proteins, lamanin and collagen, 
play a significant role in influencing cell proliferation through their 
interaction with integrin receptors. One explanation for our observed 
decrease in cellular proliferation could stem from the lack of paracrine 
interactions via integrin receptors with lamanin and collagen that stimulate 
cell growth (Albini and Sporn; Shattil, Kim, and Ginsberg).  
Another hallmark of cancer is invasion (Hanahan and Weinberg). 
Previous work by Portes et al. showed that QSOX1 is ubiquitously 
expressed in rat embryos eventually localizing to the testis a few days 
after birth. Numerous proteins involved in epithelial-to-mesenchymal 
transition that are expressed during development are reactivated during 
tumor progression contributing to tumor cell migration (Katz et al.; Chaffer 
and Weinberg; Maier, Wirth, and Beug). We hypothesized that the over-
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expression of QSOX1 in pancreatic and breast tumor cells may contribute 
to their ability to degrade basement membranes, leading to an invasive 
and metastatic phenotype.  We discovered that suppression of QSOX1 
protein resulted in a dramatic reduction in the ability of both pancreatic 
and breast tumor cells to invade through Matrigel and non-Matrigel coated 
inserts in vitro (Figure 6, 7, 13 and 14). 
Initially our results in both BxPC3 and Panc-1 cells led us to 
hypothesize that QSOX1 is a marker of highly aggressive tumors and 
therefore would not be expressed as strongly in cell lines that are poorly 
invasive. MCF7 cells are a poorly invasive luminal-like breast cancer cell 
line, while BT549 cells are a basal-like highly invasive cell line (Blick, 
Widodo, Hugo, Waltham, Lenburg, Neve, and E. W. Thompson). 
Surprisingly we discovered that QSOX1 expression is higher in MCF7 and 
other luminal-like cell lines compared to BT549 and other basal-like cell 
lines (Figure 10). Although the invasive capabilities are dramatically 
different between these two cell lines, QSOX1 knock-down suppressed 
growth and invasion in both cell lines. This finding indicates that the 
advantage QSOX1 provides to breast and pancreas tumors may be 
universal among phenotypically different tumors of different histological 
origin. However, one cannot draw this definitive conclusion from the 
behavior of cells cultured in 2D (Martin et al.; Rizki et al.).  The relevance 
of QSOX1 is likely to become functionally relevant when considered not 
only in specific molecular subcontext (such as ER+ tumor cells), but in 
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specific environmental contexts within the 3D pancreatic and breast tumor 
microenvoronment with the full complement and complex interplay of 
autocrine and paracrine signaling components known to be important in 
tumor progression (Polyak; Michor and Polyak; Hu and Polyak). 
While our results show that the loss of QSOX1 affects tumor cell motility, 
the loss of motility does not completely explain the dramatic decrease in 
the cells ability to degrade Matrigel suggesting that there are 
compensatory mechanisms contributing to overall decrease in the invasive 
abilities of the tumor cells. These results demonstrate that there are clear 
differences between the capacities of BxPC3, Panc-1, MCF7 and BT549 
to degrade basement membrane components and invade through the 
membrane. This could be due to a myriad of factors such as other 
proteases secreted, the stage and subtype of the tumor and genetic 
differences between the cell lines (Deer et al.). To determine if this 
reasoning was correct, we performed gelatin zymography as a way to 
analyze the matrix metalloproteinase activity. There are 23 known human 
MMPs as well as 4 known tissue inhibitors of MMPs (TIMP) that aid in 
regulating the expression and activation of these proteolytic enzymes 
(Tallant, Marrero, and Gomis-Rüth). MMPs are zinc-dependent proteolytic 
enzymes that degrade ECM components (Kessenbrock, Plaks, and 
Werb).  The expression patterns of MMPs are variable depending on 
tumor type, and even individual cell line.  
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 As a sulfhydryl oxidase, it is unlikely that QSOX1 would directly 
degrade basement membrane components.  Therefore, we hypothesized 
that MMPs serve as a substrate of QSOX1 while the MMPs are folding 
and undergoing activation as they are secreted from tumor cells. If true, 
suppression of QSOX1 would lead to a decrease in MMP functional 
activity, though not necessarily the amount of MMPs produced or 
secreted. Although the MMP profiles of BxPC3, Panc-1, MCF7 and BT549 
cells differ as seen in figure 8A, B and 15A, B, we found that suppression 
of QSOX1 leads to a decrease in pro-MMP-2 and -9 activity.  
In pancreatic and breast cancer the majority of MMPs are secreted 
in their inactive form and activated extracellularly (Tallant, Marrero, and 
Gomis-Rüth; Bauvois).  Activation of MMPs occurs through the release of 
a covalent Cys73–Zn2+ bond (“Cysteine Switch”) and through cleavage and 
activation by plasmin, serine proteases, and other MMPs or TIMPs as well 
as interactions with basement membrane components such as lamanin, 
collagen and fibronectin (Tallant, Marrero, and Gomis-Rüth; Kessenbrock, 
Plaks, and Werb; E. S. Radisky and D. C. Radisky).  It is possible that 
QSOX1 helps to re-fold MMPs after the cysteine switch and cleavage of 
pro-domain.  Thiol binding proteins such as glutathione have been shown 
to help fold and activate MMPs (Kessenbrock, Plaks, and Werb). MMP-2 
and -9 play an important role in pancreatic and breast cancer progression 
with 93% of tumors expressing MMP-2 compared to normal tissue 
(Bloomston, Zervos, and Rosemurgy; Köhrmann et al.). While reports 
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implicating MMP-9 in the progression of pancreatic cancer are limited, 
Tian reported the proteomic identification of MMP-9 in pancreatic juice 
from patients with pancreatic ductal adenocarcinoma (Tian et al.). 
Pryczynicz et al. also found a relationship between MMP-9 expression and 
lymph node metastases (Pryczynicz et al.).  Numerous reports implicate 
MMP-2 as a prominent protease responsible for pancreatic tumor 
metastasis (Bloomston, Zervos, and Rosemurgy; Köhrmann et al.; 
Bauvois).  
One of the benefits of gelatin zymography is that it a.) provides a 
functional measure of the activities of MMPs able to degrade gelatin and 
b.) differentiates each precursor and active MMP by molecular weight 
(Snoek-van Beurden and den Hoff; Tallant, Marrero, and Gomis-Rüth).  A 
limitation of the zymography shown here is that it is limited to MMPs 
whose substrate is gelatin.  It is possible that QSOX1 is involved in 
activation of other MMPs with different substrates as well as any one of 
the other proteases involved in degradation of basement membrane 
components.  This may be investigated in future work.  
Following up on our initial hypothesis regarding MMP activation by 
QSOX1 we performed a western blot analysis on total cellular lysate from 
MCF7, BT549, BxPC3 and Panc-1 shRNA treated cell lines. Our result 
revealed that the overall levels of secreted MMP-2 and -9 are nearly equal 
among the untreated, shScramble and shQSOX1 treated samples leading 
us to further hypothesize that QSOX1 is involved in the proper folding of 
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MMPs before they are secreted and that the loss of QSOX1 leads to 
proteolytically inactive MMPs as shown in figure 8 and 15. To further 
confirm our conclusions that MMP activation is a post-translational event, 
we performed qPCR on BxPC3, Panc-1, MCF7 and BT549 shQSOX1 
treated cells. Our observation was surprising in that we are able to show 
that there is an overall increase in the transcription of MMP-2 and -9 in 
BxPC3, Panc-1 and BT549 cells while MCF7 showed a slight decrease in 
MMP-2 and -9 expression compared to our shScrambled control. This 
result led us to hypothesize that the cell is transcriptionally attempting to 
compensate for the proteolytically inactive MMPs through an as yet 
undetermined mechanism.  
It is not known if QSOX1 aids in the proper folding of MMPs 
intracellularly or extracellularly, or if it cooperates with protein disulfide 
isomerase while MMPs are folding in the ER and golgi. Since MMPs are 
secreted extracellularly where they may undergo autoactivation or 
cleavage with proteases such as plasmin, it is possible that QSOX1-S 
activates them in the extracellular environment.  To further understand this 
interaction it would be useful to determine the preferred pattern of 
substrates for QSOX1. 
At this point, the post-translational mechanism by which QSOX1 
activates MMPs is not clear.  Our results indicate that MMP-2 and -9 RNA 
increased in shQSOX1 transduced cells.  We expected no difference in 
MMP levels, but an increase might suggest that the cells are attempting to 
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compensate for the lack of MMP activity through a feedback loop (Wu). 
Although we hypothesize that QSOX1 may activate MMPs directly by 
involvement in the cysteine switch activation mechanism (Snoek-van 
Beurden and den Hoff; Bloomston, Zervos, and Rosemurgy), ROS 
produced by QSOX1 may be indirectly activating MMPs, as MMP 
activation has been reported to depend on an oxidative environment (Wu).  
Our results underscore the need to further understand the role that 
QSOX1 plays in tumor and normal cells, and how at the molecular level, it 
activates MMPs, helps drive tumor cell growth and contributes to cell 
motility.  This information will be useful during development of inhibitors of 
QSOX1 that may work upstream of individual MMPs. QSOX1 is expressed 
during embryonic development in mouse and rat during key migratory 
stages (Andrade, Stolf, Debbas, Rosa, Kalil, Coelho, and Laurindo). This 
developmental data combined with our results indicating that QSOX1 
expression facilitates degradation of basement membranes suggests that 
tumor cells over-express QSOX1 to allow them to degrade basement 
membranes and invade into adjacent tissues or into circulation.   
QSOX1 expression in luminal B breast cancer subtype may help 
further stratify which tumors are likely to be more aggressive, leading to 
poor overall survival.  If confirmed by other groups, our finding that 
QSOX1 is a predictor of poor OS and RFS in luminal types of breast 
cancer may provide another tool for physicians and their patients to decide 
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whether to more aggressively treat patients whose tumors express high 
levels of QSOX1. 
The role of QSOX1 in cancer progression is only now beginning to 
be understood. Within this thesis we have shown that QSOX1, a novel 
protein in the field of cancer biology, is involved in several steps in the 
hallmark of cancer. Future studies determining the substrates that QSOX1 
interacts with will not only aid in our basic understanding of tumor biology 
but will also allow us to combine anti-neoplastic agents with QSOX1 
inhibitors providing us with the opportunity to slow the growth and invasive 
potential of tumor cells.   
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